1
|
Buchalet C, Loap P, Losa S, Laas E, Gaillard T, Lecuru F, Malhaire C, Huchet V, De La Rochefordiere A, Labib A, Kissel M. Long-term clinical outcomes of preoperative brachytherapy in early-stage cervical cancer. Eur J Surg Oncol 2024; 50:108342. [PMID: 38636247 DOI: 10.1016/j.ejso.2024.108342] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/16/2024] [Revised: 04/09/2024] [Accepted: 04/12/2024] [Indexed: 04/20/2024]
Abstract
OBJECTIVE The treatment of early-stage cervical cancer (CC) is primarily based on surgery. Adjuvant (chemo)radiotherapy can be necessary in presence of risk factors for relapse (tumor size, deep stromal invasion, lymphovascular space invasion (LVSI), positive margins, parametrial or lymph node involvement), increasing the risk of treatment toxicity. Preoperative brachytherapy can reduce tumor extension before surgery, potentially limiting the need for adjuvant radiotherapy. This study reports long-term clinical outcomes on efficacy and toxicity of preoperative pulse-dose-rate (PDR) brachytherapy in early-stage CC. METHODS All patients treated at Institut Curie between 2007 and 2022 for early-stage CC by preoperative brachytherapy were included. A PDR technique was used. Patients underwent hysterectomy associated with nodal staging following brachytherapy. RESULTS 73 patients were included. The median time from brachytherapy to surgery was 45 days [range: 25-78 days]. With a median follow-up of 51 months [range: 4-185], we reported 3 local (4 %), 1 locoregional (1 %) and 8 metastatic (11 %) relapses. At 10 years, OS was 84.1 % [95 % CI: 70.0-100], DFS 84.3 % [95 % CI:74.6-95.3] and LRFS 92.8 % [95 % CI:84.8-100]. Persistence of a tumor residue, observed in 32 patients (44 %), was a significant risk factor for metastatic relapse (p = 0.02) and was associated with the largest tumor size before brachytherapy (p = 0.04). Five patients (7 %) experienced grade 3 toxicity. One patient (1 %) developed grade 4 toxicity. Ten patients (14 %) received adjuvant radiotherapy, increasing the risk of lymphedema (HR 1.31, 95 % CI [1.11-1.54]; p = 0.002). CONCLUSIONS PDR preoperative brachytherapy for early-stage cervical cancer provides high long-term tumor control rates with low toxicity.
Collapse
Affiliation(s)
- C Buchalet
- Radiation Oncology Department, Institut Curie, Paris, France
| | - P Loap
- Radiation Oncology Department, Institut Curie, Paris, France
| | - S Losa
- Medical Physics Department, Institut Curie, Paris, France
| | - E Laas
- Surgical Oncology Department, Institut Curie, Paris, France
| | - T Gaillard
- Surgical Oncology Department, Institut Curie, Paris, France
| | - F Lecuru
- Surgical Oncology Department, Institut Curie, Paris, France
| | - C Malhaire
- Radiology Department, Institut Curie, Paris, France
| | - V Huchet
- Nuclear Medicine Department, Institut Curie, Paris, France
| | - A De La Rochefordiere
- Radiation Oncology Department, Centre Charlebourg-La Défense-Amethyst, La Garenne-Colombes, France
| | - A Labib
- Radiation Oncology Department, Institut Curie, Paris, France
| | - M Kissel
- Radiation Oncology Department, Institut Curie, Paris, France.
| |
Collapse
|
2
|
Hannoun-Lévi JM, Savignoni A, Féron JG, Malhaire C, Ezzili C, Brédart A, Loap P, Kirova Y. Management of second ipsilateral breast tumor event: An advocacy for a randomized trial. Cancer Radiother 2024; 28:188-194. [PMID: 38216433 DOI: 10.1016/j.canrad.2023.11.001] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/14/2023] [Revised: 11/07/2023] [Accepted: 11/21/2023] [Indexed: 01/14/2024]
Abstract
For a second ipsilateral breast tumor event, salvage mastectomy is the standard of care while second conservative treatment is a possible option. However, level 1 proofs are missing, leading to perform salvage mastectomy for patients who could receive second conservative treatment and consequently avoid psychological/quality of life salvage mastectomy deleterious impacts. A phase 3 randomized trial comparing salvage mastectomy to second conservative treatment is needed. Here we discuss what would be to us the optimal design of such trial to confirm the non-inferiority between the two salvage options, with a focus on methodological aspects in terms of patient characteristics and statistical issues.
Collapse
Affiliation(s)
- J-M Hannoun-Lévi
- Department of Radiation Oncology, centre Antoine-Lacassagne, université Côte d'Azur, Nice, France.
| | - A Savignoni
- Department of Biostatistics, institut Curie, Paris, France
| | - J-G Féron
- Department of Breast Surgery, institut Curie, Paris, France
| | - C Malhaire
- Department of Medical Imaging, institut Curie, Paris, France
| | - C Ezzili
- Department of Clinical Research, institut Curie, Paris, France
| | - A Brédart
- Psycho-Oncology Unit, institut Curie, Paris, France
| | - P Loap
- Department of Radiation Oncology, institut Curie, Paris, France
| | - Y Kirova
- Department of Radiation Oncology, institut Curie, Paris, France
| |
Collapse
|
3
|
Richaud C, Jochum F, Journo G, Toussaint A, Laurent M, Fontier Z, Langer A, Malhaire C, Laas E, Féron JG, Lecuru F, Pouget N, Guinebretière JM, El Zein S, Brain E, Watson S, Piperno-Neumann S, Blay JY, Bonvalot S, Bozec L, Hamy AS. Impact of guideline adherence and expert center referral on the early management and outcomes of uterine sarcoma patients: A retrospective analysis from the French NETSARC network. Eur J Surg Oncol 2024; 50:107319. [PMID: 38159391 DOI: 10.1016/j.ejso.2023.107319] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/04/2023] [Revised: 11/21/2023] [Accepted: 12/07/2023] [Indexed: 01/03/2024]
Abstract
OBJECTIVE Uterine sarcomas are rare tumors with a poor prognosis. Their diagnosis is often incidental, following surgery. Our goal was to examine the early management strategies for uterine sarcomas, and to assess the impact of guideline adherence and expert center referral on both the management approaches and the clinical outcomes in patients with uterine sarcomas. METHODS We retrospectively analyzed medical records from patients with uterine sarcoma referred to the Institut Curie and registered in the database of the French NETSARC network. RESULTS In total, 100 patients, with a median age of 54 years, were included in the analyses. On MRI scans (n = 36), all patients had at least two signs suggestive of malignancy, and 77.8 % had four or more signs. No preoperative biopsy was performed in 65.6 % of cases. Only 14.1 % of patients underwent initial surgery at an expert center. Surgery performed outside the network was significantly associated with morcellation (32.9 % vs. 0 %; p = 0.036), fewer negative margins (R0 margins 52.4 % vs. 100 %; p = 0.006), and poor adherence to surgical guidelines (28.3 vs. 72.7 %; p = 0.013). Multivariate analysis showed that non-adherence to surgical recommendations was not significantly associated with relapse-free survival (HR = 0.54; 95 % CI [0.21-1.38]), but was an independent predictor of poor overall survival (HR = 0.12; 95 % CI [0.03-0.52]; p = 0.005). CONCLUSION Despite a high frequency of suspicious clinical and radiological signs, a large proportion of women undergoing sarcoma surgery are treated outside of expert networks. We provide guidelines, integrating the clinical context and radiological signs to encourage early referral to reference centers for sarcoma.
Collapse
Affiliation(s)
- Clarisse Richaud
- Department of Gynecology, Cochin Port-Royal Hospital, Paris, France
| | - Floriane Jochum
- Department of Gynecology, Strasbourg University Hospital, Strasbourg, France; Residual Tumor & Response to Treatment Laboratory, RT2Lab, Translational Research Department, INSERM, U932 Immunity and Cancer, Université Paris Cité, Paris, France
| | | | | | | | | | - Adriana Langer
- Department of Radiology, Institut Curie, Saint Cloud, France
| | | | - Enora Laas
- Department of Breast, Gynecological and Reconstructive Surgery, Institut Curie, Université Paris Cité, Paris, France
| | - Jean-Guillaume Féron
- Department of Breast, Gynecological and Reconstructive Surgery, Institut Curie, Université Paris Cité, Paris, France
| | - Fabrice Lecuru
- Department of Breast, Gynecological and Reconstructive Surgery, Institut Curie, Université Paris Cité, Paris, France
| | - Nicolas Pouget
- Department of Breast, Gynecological and Reconstructive Surgery, Institut Curie, Saint-Cloud, France
| | | | - Sophie El Zein
- Department of Pathology, Institut Curie, Université PSL, Paris, France
| | - Etienne Brain
- Department of Medical Oncology, Institut Curie, Saint Cloud, France
| | - Sarah Watson
- Department of Medical Oncology, Universite Paris Cite, Paris, France
| | | | - Jean-Yves Blay
- Department of Medical Oncology, Center Léon Bérard, Lyon, France
| | - Sylvie Bonvalot
- Department of Surgical Oncology, Institut Curie, Université Paris Cité, Paris, France
| | - Laurence Bozec
- Department of Medical Oncology, Institut Curie, Saint Cloud, France
| | - Anne-Sophie Hamy
- Residual Tumor & Response to Treatment Laboratory, RT2Lab, Translational Research Department, INSERM, U932 Immunity and Cancer, Université Paris Cité, Paris, France.
| |
Collapse
|
4
|
Malhaire C. Radiomics in 18F-FDG PET/CT predicts HER2 status in breast cancer with equivocal immunohistochemistry. Eur J Radiol 2024; 170:111238. [PMID: 38043379 DOI: 10.1016/j.ejrad.2023.111238] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/22/2023] [Accepted: 11/25/2023] [Indexed: 12/05/2023]
Affiliation(s)
- Caroline Malhaire
- Institut Curie, Department of Medical Imaging, PSL Research University, 26 rue d'Ulm, 75005 Paris, France; Institut Curie, Research Center, U1288-LITO, Inserm, Paris-Saclay University, 91401 Orsay, France.
| |
Collapse
|
5
|
Malhaire C, Selhane F, Saint-Martin MJ, Cockenpot V, Akl P, Laas E, Bellesoeur A, Ala Eddine C, Bereby-Kahane M, Manceau J, Sebbag-Sfez D, Pierga JY, Reyal F, Vincent-Salomon A, Brisse H, Frouin F. Exploring the added value of pretherapeutic MR descriptors in predicting breast cancer pathologic complete response to neoadjuvant chemotherapy. Eur Radiol 2023; 33:8142-8154. [PMID: 37318605 DOI: 10.1007/s00330-023-09797-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/15/2022] [Revised: 04/14/2023] [Accepted: 05/13/2023] [Indexed: 06/16/2023]
Abstract
OBJECTIVES To evaluate the association between pretreatment MRI descriptors and breast cancer (BC) pathological complete response (pCR) to neoadjuvant chemotherapy (NAC). MATERIALS AND METHODS Patients with BC treated by NAC with a breast MRI between 2016 and 2020 were included in this retrospective observational single-center study. MR studies were described using the standardized BI-RADS and breast edema score on T2-weighted MRI. Univariable and multivariable logistic regression analyses were performed to assess variables association with pCR according to residual cancer burden. Random forest classifiers were trained to predict pCR on a random split including 70% of the database and were validated on the remaining cases. RESULTS Among 129 BC, 59 (46%) achieved pCR after NAC (luminal (n = 7/37, 19%), triple negative (n = 30/55, 55%), HER2 + (n = 22/37, 59%)). Clinical and biological items associated with pCR were BC subtype (p < 0.001), T stage 0/I/II (p = 0.008), higher Ki67 (p = 0.005), and higher tumor-infiltrating lymphocytes levels (p = 0.016). Univariate analysis showed that the following MRI features, oval or round shape (p = 0.047), unifocality (p = 0.026), non-spiculated margins (p = 0.018), no associated non-mass enhancement (p = 0.024), and a lower MRI size (p = 0.031), were significantly associated with pCR. Unifocality and non-spiculated margins remained independently associated with pCR at multivariable analysis. Adding significant MRI features to clinicobiological variables in random forest classifiers significantly increased sensitivity (0.67 versus 0.62), specificity (0.69 versus 0.67), and precision (0.71 versus 0.67) for pCR prediction. CONCLUSION Non-spiculated margins and unifocality are independently associated with pCR and can increase models performance to predict BC response to NAC. CLINICAL RELEVANCE STATEMENT A multimodal approach integrating pretreatment MRI features with clinicobiological predictors, including tumor-infiltrating lymphocytes, could be employed to develop machine learning models for identifying patients at risk of non-response. This may enable consideration of alternative therapeutic strategies to optimize treatment outcomes. KEY POINTS • Unifocality and non-spiculated margins are independently associated with pCR at multivariable logistic regression analysis. • Breast edema score is associated with MR tumor size and TIL expression, not only in TN BC as previously reported, but also in luminal BC. • Adding significant MRI features to clinicobiological variables in machine learning classifiers significantly increased sensitivity, specificity, and precision for pCR prediction.
Collapse
Affiliation(s)
- Caroline Malhaire
- Department of Medical Imaging, Institut Curie, PSL Research University, 26 Rue d'Ulm, 75005, Paris, France.
- Institut Curie, Research Center, U1288-LITO, Inserm, Paris-Saclay University, 91401, Orsay, France.
| | - Fatine Selhane
- Gustave Roussy, Department of Imaging, Paris-Saclay University, 94805, Villejuif, France
| | | | - Vincent Cockenpot
- Pathology Unit, Centre Léon Bérard, 28 Rue Laennec, 69008, Lyon, France
| | - Pia Akl
- Women Imaging Unit, HCL, Radiologie du Groupement Hospitalier Est, 3 Quai Des Célestins, 69002, Lyon, France
| | - Enora Laas
- Department of Surgical Oncology, Institut Curie, 26 Rue d'Ulm, 75005, Paris, France
| | - Audrey Bellesoeur
- Department of Medical Oncology, Institut Curie, 26 Rue d'Ulm, 75005, Paris, France
| | - Catherine Ala Eddine
- Department of Medical Imaging, Institut Curie, PSL Research University, 26 Rue d'Ulm, 75005, Paris, France
| | - Melodie Bereby-Kahane
- Department of Medical Imaging, Institut Curie, PSL Research University, 26 Rue d'Ulm, 75005, Paris, France
| | - Julie Manceau
- Department of Medical Imaging, Institut Curie, PSL Research University, 26 Rue d'Ulm, 75005, Paris, France
| | - Delphine Sebbag-Sfez
- Department of Medical Imaging, Institut Curie, PSL Research University, 26 Rue d'Ulm, 75005, Paris, France
| | - Jean-Yves Pierga
- Department of Medical Oncology, Institut Curie, 26 Rue d'Ulm, 75005, Paris, France
| | - Fabien Reyal
- Department of Surgical Oncology, Institut Curie, 26 Rue d'Ulm, 75005, Paris, France
| | | | - Herve Brisse
- Department of Medical Imaging, Institut Curie, PSL Research University, 26 Rue d'Ulm, 75005, Paris, France
| | - Frederique Frouin
- Institut Curie, Research Center, U1288-LITO, Inserm, Paris-Saclay University, 91401, Orsay, France
| |
Collapse
|
6
|
Ramtohul T, Djerroudi L, Lissavalid E, Nhy C, Redon L, Ikni L, Djelouah M, Journo G, Menet E, Cabel L, Malhaire C, Tardivon A. Multiparametric MRI and Radiomics for the Prediction of HER2-Zero, -Low, and -Positive Breast Cancers. Radiology 2023; 308:e222646. [PMID: 37526540 DOI: 10.1148/radiol.222646] [Citation(s) in RCA: 5] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 08/02/2023]
Abstract
Background Half of breast cancers exhibit low expression levels of human epidermal growth factor receptor 2 (HER2) and can be targeted by new antibody-drug conjugates. The imaging differences between HER2-zero (immunohistochemistry [IHC] score of 0), HER2-low (IHC score of 1+ or 2+ with negative findings at fluorescence in situ hybridization [FISH]), and HER2-positive (IHC score of 2+ with positive findings at FISH or IHC score of 3+) breast cancers were unknown. Purpose To assess whether multiparametric dynamic contrast-enhanced MRI-based radiomic features can help distinguish HER2 expressions in breast cancer. Materials and Methods This study included women with breast cancer who underwent MRI at two different centers between December 2020 and December 2022. Tumor segmentation and radiomic feature extraction were performed on T2-weighted and dynamic contrast-enhanced T1-weighted images. Unsupervised correlation analysis of reproducible features and least absolute shrinkage and selector operation were used for the selection of features to build a radiomics signature. The area under the receiver operating characteristic curve (AUC) was used to assess the performance of the radiomic signature. Multivariable logistic regression was used to identify independent predictors for distinguishing HER2 expressions in both the training and prospectively acquired external data set. Results The training set included 208 patients from center 1 (mean age, 53 years ± 14 [SD]), and the external test set included 131 patients from center 2 (mean age, 54 years ± 13). In the external test data set, the radiomic signature achieved an AUC of 0.80 (95% CI: 0.71, 0.89) for distinguishing HER2-low and -positive tumors versus HER2-zero tumors and was a significant predictive factor for distinguishing these two groups (odds ratio = 7.6; 95% CI: 2.9, 19.8; P < .001). Among HER2-low or -positive breast cancers, histology type, associated nonmass enhancement, and multiple lesions at MRI had an AUC of 0.77 (95% CI: 0.68, 0.86) in the external test set for the prediction of HER2-positive versus HER2-low cancers. Conclusion The radiomic signature and tumor descriptors from multiparametric breast MRI may predict distinct HER2 expressions of breast cancers with therapeutic implications. © RSNA, 2023 Supplemental material is available for this article. See also the editorial by Kataoka and Honda in this issue.
Collapse
Affiliation(s)
- Toulsie Ramtohul
- From the Department of Radiology (T.R., E.L., C.N., L.R., L.I., M.D., C.M., A.T.), Department of Diagnostic and Theranostic Medicine-Pathology (L.D.), and Department of Medical Oncology (L.C.), Institut Curie Paris, PSL Research University, 26 rue d'Ulm, Paris, France; Department of Radiology (G.J.) and Department of Diagnostic and Theranostic Medicine-Pathology (E.M.), Institut Curie St Cloud, PSL Research University, St Cloud, France
| | - Lounes Djerroudi
- From the Department of Radiology (T.R., E.L., C.N., L.R., L.I., M.D., C.M., A.T.), Department of Diagnostic and Theranostic Medicine-Pathology (L.D.), and Department of Medical Oncology (L.C.), Institut Curie Paris, PSL Research University, 26 rue d'Ulm, Paris, France; Department of Radiology (G.J.) and Department of Diagnostic and Theranostic Medicine-Pathology (E.M.), Institut Curie St Cloud, PSL Research University, St Cloud, France
| | - Emilie Lissavalid
- From the Department of Radiology (T.R., E.L., C.N., L.R., L.I., M.D., C.M., A.T.), Department of Diagnostic and Theranostic Medicine-Pathology (L.D.), and Department of Medical Oncology (L.C.), Institut Curie Paris, PSL Research University, 26 rue d'Ulm, Paris, France; Department of Radiology (G.J.) and Department of Diagnostic and Theranostic Medicine-Pathology (E.M.), Institut Curie St Cloud, PSL Research University, St Cloud, France
| | - Caroline Nhy
- From the Department of Radiology (T.R., E.L., C.N., L.R., L.I., M.D., C.M., A.T.), Department of Diagnostic and Theranostic Medicine-Pathology (L.D.), and Department of Medical Oncology (L.C.), Institut Curie Paris, PSL Research University, 26 rue d'Ulm, Paris, France; Department of Radiology (G.J.) and Department of Diagnostic and Theranostic Medicine-Pathology (E.M.), Institut Curie St Cloud, PSL Research University, St Cloud, France
| | - Louis Redon
- From the Department of Radiology (T.R., E.L., C.N., L.R., L.I., M.D., C.M., A.T.), Department of Diagnostic and Theranostic Medicine-Pathology (L.D.), and Department of Medical Oncology (L.C.), Institut Curie Paris, PSL Research University, 26 rue d'Ulm, Paris, France; Department of Radiology (G.J.) and Department of Diagnostic and Theranostic Medicine-Pathology (E.M.), Institut Curie St Cloud, PSL Research University, St Cloud, France
| | - Laura Ikni
- From the Department of Radiology (T.R., E.L., C.N., L.R., L.I., M.D., C.M., A.T.), Department of Diagnostic and Theranostic Medicine-Pathology (L.D.), and Department of Medical Oncology (L.C.), Institut Curie Paris, PSL Research University, 26 rue d'Ulm, Paris, France; Department of Radiology (G.J.) and Department of Diagnostic and Theranostic Medicine-Pathology (E.M.), Institut Curie St Cloud, PSL Research University, St Cloud, France
| | - Manel Djelouah
- From the Department of Radiology (T.R., E.L., C.N., L.R., L.I., M.D., C.M., A.T.), Department of Diagnostic and Theranostic Medicine-Pathology (L.D.), and Department of Medical Oncology (L.C.), Institut Curie Paris, PSL Research University, 26 rue d'Ulm, Paris, France; Department of Radiology (G.J.) and Department of Diagnostic and Theranostic Medicine-Pathology (E.M.), Institut Curie St Cloud, PSL Research University, St Cloud, France
| | - Gabrielle Journo
- From the Department of Radiology (T.R., E.L., C.N., L.R., L.I., M.D., C.M., A.T.), Department of Diagnostic and Theranostic Medicine-Pathology (L.D.), and Department of Medical Oncology (L.C.), Institut Curie Paris, PSL Research University, 26 rue d'Ulm, Paris, France; Department of Radiology (G.J.) and Department of Diagnostic and Theranostic Medicine-Pathology (E.M.), Institut Curie St Cloud, PSL Research University, St Cloud, France
| | - Emmanuelle Menet
- From the Department of Radiology (T.R., E.L., C.N., L.R., L.I., M.D., C.M., A.T.), Department of Diagnostic and Theranostic Medicine-Pathology (L.D.), and Department of Medical Oncology (L.C.), Institut Curie Paris, PSL Research University, 26 rue d'Ulm, Paris, France; Department of Radiology (G.J.) and Department of Diagnostic and Theranostic Medicine-Pathology (E.M.), Institut Curie St Cloud, PSL Research University, St Cloud, France
| | - Luc Cabel
- From the Department of Radiology (T.R., E.L., C.N., L.R., L.I., M.D., C.M., A.T.), Department of Diagnostic and Theranostic Medicine-Pathology (L.D.), and Department of Medical Oncology (L.C.), Institut Curie Paris, PSL Research University, 26 rue d'Ulm, Paris, France; Department of Radiology (G.J.) and Department of Diagnostic and Theranostic Medicine-Pathology (E.M.), Institut Curie St Cloud, PSL Research University, St Cloud, France
| | - Caroline Malhaire
- From the Department of Radiology (T.R., E.L., C.N., L.R., L.I., M.D., C.M., A.T.), Department of Diagnostic and Theranostic Medicine-Pathology (L.D.), and Department of Medical Oncology (L.C.), Institut Curie Paris, PSL Research University, 26 rue d'Ulm, Paris, France; Department of Radiology (G.J.) and Department of Diagnostic and Theranostic Medicine-Pathology (E.M.), Institut Curie St Cloud, PSL Research University, St Cloud, France
| | - Anne Tardivon
- From the Department of Radiology (T.R., E.L., C.N., L.R., L.I., M.D., C.M., A.T.), Department of Diagnostic and Theranostic Medicine-Pathology (L.D.), and Department of Medical Oncology (L.C.), Institut Curie Paris, PSL Research University, 26 rue d'Ulm, Paris, France; Department of Radiology (G.J.) and Department of Diagnostic and Theranostic Medicine-Pathology (E.M.), Institut Curie St Cloud, PSL Research University, St Cloud, France
| |
Collapse
|
7
|
Rodrigues M, Vanoni G, Loap P, Dubot C, Timperi E, Minsat M, Bazire L, Durdux C, Fourchotte V, Laas E, Pouget N, Castel-Ajgal Z, Marret G, Lesage L, Meseure D, Vincent-Salomon A, Lecompte L, Servant N, Vacher S, Bieche I, Malhaire C, Huchet V, Champion L, Kamal M, Amigorena S, Lantz O, Chevrier M, Romano E. Nivolumab plus chemoradiotherapy in locally-advanced cervical cancer: the NICOL phase 1 trial. Nat Commun 2023; 14:3698. [PMID: 37349318 PMCID: PMC10287640 DOI: 10.1038/s41467-023-39383-8] [Citation(s) in RCA: 7] [Impact Index Per Article: 7.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/06/2023] [Accepted: 06/12/2023] [Indexed: 06/24/2023] Open
Abstract
Concurrent chemoradiotherapy (CRT) with blockade of the PD-1 pathway may enhance immune-mediated tumor control through increased phagocytosis, cell death, and antigen presentation. The NiCOL phase 1 trial (NCT03298893) is designed to determine the safety/tolerance profile and the recommended phase-II dose of nivolumab with and following concurrent CRT in 16 women with locally advanced cervical cancer. Secondary endpoints include objective response rate (ORR), progression free survival (PFS), disease free survival, and immune correlates of response. Three patients experience grade 3 dose-limiting toxicities. The pre-specified endpoints are met, and overall response rate is 93.8% [95%CI: 69.8-99.8%] with a 2-year PFS of 75% [95% CI: 56.5-99.5%]. Compared to patients with progressive disease (PD), progression-free (PF) subjects show a brisker stromal immune infiltrate, higher proximity of tumor-infiltrating CD3+ T cells to PD-L1+ tumor cells and of FOXP3+ T cells to proliferating CD11c+ myeloid cells. PF show higher baseline levels of PD-1 and ICOS-L on tumor-infiltrating EMRA CD4+ T cells and tumor-associated macrophages, respectively; PD instead, display enhanced PD-L1 expression on TAMs, higher peripheral frequencies of proliferating Tregs at baseline and higher PD-1 levels at week 6 post-treatment initiation on CD4 and CD8 T cell subsets. Concomitant nivolumab plus definitive CRT is safe and associated with encouraging PFS rates. Further validation in the subset of locally advanced cervical cancer displaying pre-existing, adaptive immune activation is warranted.
Collapse
Affiliation(s)
- Manuel Rodrigues
- Department of Medical Oncology, Institut Curie, Paris & Saint-Cloud, France
| | - Giulia Vanoni
- Center for Cancer Immunotherapy, INSERM U932, PSL Research University, Institut Curie, Paris, France
| | - Pierre Loap
- Department of Radiation Oncology, Institut Curie, Paris & Saint Cloud, France
| | - Coraline Dubot
- Department of Medical Oncology, Institut Curie, Paris & Saint-Cloud, France
| | - Eleonora Timperi
- Center for Cancer Immunotherapy, INSERM U932, PSL Research University, Institut Curie, Paris, France
| | - Mathieu Minsat
- Department of Radiation Oncology, Institut Curie, Paris & Saint Cloud, France
| | - Louis Bazire
- Department of Radiation Oncology, Institut Curie, Paris & Saint Cloud, France
| | - Catherine Durdux
- Hôpital Européen Georges Pompidou, Department of Radiation Oncology, Paris, France
| | | | - Enora Laas
- Service of Breast and Gynecologic Surgery, Institut Curie, Paris, France
| | - Nicolas Pouget
- Service of Breast and Gynecologic Surgery, Institut Curie, Paris, France
| | - Zahra Castel-Ajgal
- Department of Drug Development and Innovation, Institut Curie, Paris, France
| | - Gregoire Marret
- Department of Drug Development and Innovation, Institut Curie, Paris, France
| | - Laetitia Lesage
- Department of Pathology Institut Curie, Paris, France
- Centre d'Investigation Clinique Biothérapie, Institut Curie, Paris, France
| | - Didier Meseure
- Department of Pathology Institut Curie, Paris, France
- Centre d'Investigation Clinique Biothérapie, Institut Curie, Paris, France
| | - Anne Vincent-Salomon
- Department of Pathology Institut Curie, Paris, France
- Centre d'Investigation Clinique Biothérapie, Institut Curie, Paris, France
| | - Lolita Lecompte
- Institut Curie Bioinformatics Platform, INSERM U900, Mines ParisTech, Paris, 75005, France
| | - Nicolas Servant
- Institut Curie Bioinformatics Platform, INSERM U900, Mines ParisTech, Paris, 75005, France
| | - Sophie Vacher
- Pharmacogenomics Unit, Service of Genetics, Institut Curie, Paris, France
| | - Ivan Bieche
- Pharmacogenomics Unit, Service of Genetics, Institut Curie, Paris, France
| | | | - Virginie Huchet
- Department of Nuclear Medicine, Institut Curie, Paris, 75005, France
| | - Laurence Champion
- Department of Nuclear Medicine, Institut Curie, Paris, 75005, France
| | - Maud Kamal
- Department of Drug Development and Innovation, Institut Curie, Paris, France
| | - Sebastian Amigorena
- Center for Cancer Immunotherapy, INSERM U932, PSL Research University, Institut Curie, Paris, France
| | - Olivier Lantz
- Center for Cancer Immunotherapy, INSERM U932, PSL Research University, Institut Curie, Paris, France
| | - Marion Chevrier
- Service of Biostatistics, Institut Curie, Paris, 75005, France
| | - Emanuela Romano
- Department of Medical Oncology, Institut Curie, Paris & Saint-Cloud, France.
- Center for Cancer Immunotherapy, INSERM U932, PSL Research University, Institut Curie, Paris, France.
| |
Collapse
|
8
|
Roussel-Simonin C, Croce S, Guyon F, Llacer C, Ray-Coquard I, Meeus P, Genestie C, Taieb S, Malhaire C, Duffaud F, Pautier P. [Uterin sarcoma, high-grade stroma, indifferenciated, referential]. Bull Cancer 2023:S0007-4551(23)00161-3. [PMID: 37062646 DOI: 10.1016/j.bulcan.2023.03.017] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/30/2022] [Revised: 03/17/2023] [Accepted: 03/20/2023] [Indexed: 04/18/2023]
Abstract
High-grade endometrial stromal sarcoma (HGESS) and uterine undifferentiated sarcoma (UUS) are rare uterine malignancies arising from mesenchymal endometrial cells. They are characterized by aggressive behavior and poor prognosis. Median age of diagnostic is 55years. The most common symptoms are vaginal bleeding, abdominal pain, and pelvic mass. Approximately 65 % are diagnosed witch advance disease stage III or IV according to the International Federation of Gynecology and Obstetrics classification. Median overall survival is around 20months. The management of the disease must be discussed in multidisciplinary staff meetings. The standard management of HGESS and UUS is total hysterectomy with bilateral oophorectomy. Systematic lymphadenectomy is not recommended. Adjuvant therapies, such as chemotherapy and radiotherapy must be discussed. In case of oligo-metastasic disease, surgery of the primary tumor and metastasis must be discussed and if not operable the standard management is doxorubine-based chemotherapy.
Collapse
Affiliation(s)
| | - Sabrina Croce
- Institut Bergonié, département de pathologie, Bordeaux, France
| | - Frédéric Guyon
- Institut Bergonié, département de chirurgie, Bordeaux, France
| | - Carmen Llacer
- Institut du Cancer de Montpellier, département de radiothérapie, Montpellier, France
| | | | - Pierre Meeus
- Centre Léon-Bérard, département de chirurgie, Lyon, France
| | | | - Sophie Taieb
- Centre Oscar-Lambret, département de radiologie, Lille, France
| | | | - Florence Duffaud
- Gustave-Roussy, département d'oncologie médicale, Villejuif, France
| | - Patricia Pautier
- Gustave-Roussy, département d'oncologie médicale, Villejuif, France
| |
Collapse
|
9
|
Saule C, Menu-Hespel S, Carton M, Malhaire C, Cherel P, Reyal F, Le Mentec M, Guillot E, Donnadieu A, Callet N, Frank S, Coussy F, Stoppa-Lyonnet D, Mouret-Fourme E. Prevalent versus incident breast cancers: benefits of clinical and radiological monitoring in women with pathogenic BRCA1/2 variants. Eur J Hum Genet 2022; 30:1060-1066. [PMID: 35217802 PMCID: PMC9436925 DOI: 10.1038/s41431-022-01049-2] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/02/2021] [Revised: 12/16/2021] [Accepted: 01/13/2022] [Indexed: 11/08/2022] Open
Abstract
Women with pathogenic germline BRCA1 or BRCA2 variants have a higher risk of breast cancer than in the general population. International guidelines recommend specific clinical and radiological breast follow-up. This specific breast screening program has already been shown to be of clinical benefit, but no information is available concerning the use of prognostic factors or specific survival to guide follow-up decisions. We evaluated "high-risk" screening in a retrospective single-center study of 520 women carrying pathogenic germline variants of the BRCA1 or BRCA2 gene treated for breast cancer between January 2000 and December 2016. We compared two groups of women: the incidental breast cancer group (IBCG) were followed before breast cancer diagnosis (N = 103), whereas the prevalent breast cancer group (PBCG) (N = 417) had no specific follow-up for high risk before breast cancer diagnosis. Breast cancers were diagnosed at an earlier stage in the IBCG than in the PBCG: T0 in 64% versus 19% of tumors, (p < 0.00001), and N0 in 90% vs. 75% (p < 0.00001), respectively. Treatment differed significantly between the 2 groups: less neoadjuvant chemotherapy (7.1% vs. 28.5%, p < 0.00001), adjuvant chemotherapy (47.7% vs. 61.9%, p = 0.004) and more mastectomies (60% vs. 42% p < 0.0001) in the IBCG vs PBCG groups respectively. Overall and breast cancer-specific mortality were similar between the two groups. However, the patients in the IBCG had a significantly longer metastasis-free survival than those in the PBCG, at three years (96.9% [95% CI 93.5-100] vs. 92.30% [95% CI 89.8-94.9]; p = 0.02), suggesting a possible long-term survival advantage.
Collapse
Affiliation(s)
- Claire Saule
- Institut Curie, Department of Genetics, PSL Research University, Paris, France.
| | | | - Matthieu Carton
- Institut Curie, Department of Biometry, DRCI, PSL Research University, Paris, France
| | - Caroline Malhaire
- Institut Curie, Department of Medical Imaging, PSL Research University, Paris, France
- Institut Curie, INSERM, LITO Laboratory, 91401, Orsay, France
| | - Pascal Cherel
- Institut Curie, Department of Medical Imaging, Saint-Cloud, France
| | - Fabien Reyal
- Institut Curie, Department of Surgery, PSL Research University, Paris, France
- Institut Curie, Residual Tumour & Response to Treatment Laboratory (RT2Lab), INSERM, U 932 Immunity and Cancer, Paris, France
| | - Marine Le Mentec
- Institut Curie, Department of Genetics, PSL Research University, Paris, France
| | | | - Anne Donnadieu
- Institut Curie, Department of Medical Oncology, Saint-Cloud, France
| | - Nasrine Callet
- Institut Curie, Department of Genetics, PSL Research University, Paris, France
- Institut Curie, Department of Medical Oncology, Saint-Cloud, France
| | - Sophie Frank
- Institut Curie, Department of Genetics, PSL Research University, Paris, France
- Institut Curie, Department of Medical Oncology, PSL Research University, Paris, France
| | - Florence Coussy
- Institut Curie, Department of Medical Oncology, PSL Research University, Paris, France
| | - Dominique Stoppa-Lyonnet
- Institut Curie, Department of Genetics, PSL Research University, Paris, France
- Institut Curie, INSERM U830, Paris, France
- Université de Paris, Paris, France
| | | |
Collapse
|
10
|
Armani M, Lissavarid É, Dyien B, Manceau J, Bereby Kahane M, Malhaire C, Tardivon A. Lésions classées ACR3 en IRM mammaire. Imagerie de la Femme 2022. [DOI: 10.1016/j.femme.2022.08.003] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
11
|
Ramtohul T, Tescher C, Vaflard P, Cyrta J, Girard N, Malhaire C, Tardivon A. Prospective Evaluation of Ultrafast Breast MRI for Predicting Pathologic Response after Neoadjuvant Therapies. Radiology 2022; 305:565-574. [PMID: 35880977 DOI: 10.1148/radiol.220389] [Citation(s) in RCA: 11] [Impact Index Per Article: 5.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Abstract
Background Ultrafast dynamic contrast-enhanced (DCE) MRI parameters are associated with breast cancer aggressiveness. However, the role of these parameters as predictive biomarkers for pathologic response after neoadjuvant chemotherapy (NAC) has been poorly investigated. Purpose To assess whether semiquantitative perfusion parameters calculated at initial ultrafast DCE MRI are associated with early prediction for pathologic response after NAC in participants with breast cancer. Materials and Methods This prospective single-center study included consecutive women with nonmetastatic invasive breast cancer treated with NAC followed by surgery who underwent initial ultrafast DCE MRI between December 2020 and August 2021. Six semiquantitative ultrafast DCE MRI parameters were calculated for each participant from the fitted time-signal intensity curve. Multivariable logistic regression was used to identify independent predictors of pathologic complete response (pCR) and residual cancer burden (RCB). Results Fifty women (mean age, 49 years ± 12 [SD]) were included in the study; 20 achieved pCR and 25 achieved low RCB (RCB-0 and I). A wash-in slope (WIS) cutoff value of 1.6% per second had a sensitivity of 94% (17 of 18 participants) and a specificity of 59% (19 of 32 participants) for pCR. A WIS of more than 1.6% per second (odds ratio [OR], 8.4 [95% CI: 1.5, 48.2]; P = .02), human epidermal growth factor receptor 2 (HER2) positivity (OR, 6.3 [95% CI: 1.5, 27.4]; P = .01), and tumor-infiltrating lymphocytes of more than 10% (OR, 6.9 [95% CI: 1.3, 37.7]; P = .03) were independent predictive factors of pCR. The area under the receiver operating characteristic curve of the three-component model, which included WIS, tumor-infiltrating lymphocytes, and HER2 positivity, was 0.92 (95% CI: 0.84, 0.99). A WIS of more than 1.6% per second was associated with higher pCR rates in the HER2-positive (OR, 21.7 [95% CI: 1.8, 260.6]; P = .02) breast cancer subgroup. For luminal HER2-negative and triple-negative breast cancers, a WIS of more than 1.6% per second was associated with low RCB (OR, 11.0 [95% CI: 1.1, 106.4]; P = .04). Conclusion The wash-in slope (WIS) assessment at initial ultrafast dynamic contrast-enhanced MRI may be used to predict pathologic complete response (pCR) in participants with breast cancer. The WIS value was used to identify two subsets of human epidermal growth factor receptor 2-positive cancers with distinct pCR rates. © RSNA, 2022 Online supplemental material is available for this article. See also the editorial by Lee and Moy in this issue.
Collapse
Affiliation(s)
- Toulsie Ramtohul
- From the Departments of Radiology (T.R., C.T., C.M., A.T.), Medical Oncology (P.V.), Diagnostic and Theranostic Medicine - Pathology (J.C.), and Surgical Oncology (N.G.), Institut Curie, PSL Research University, 26 rue d'Ulm, Paris 75005, France
| | - Clara Tescher
- From the Departments of Radiology (T.R., C.T., C.M., A.T.), Medical Oncology (P.V.), Diagnostic and Theranostic Medicine - Pathology (J.C.), and Surgical Oncology (N.G.), Institut Curie, PSL Research University, 26 rue d'Ulm, Paris 75005, France
| | - Pauline Vaflard
- From the Departments of Radiology (T.R., C.T., C.M., A.T.), Medical Oncology (P.V.), Diagnostic and Theranostic Medicine - Pathology (J.C.), and Surgical Oncology (N.G.), Institut Curie, PSL Research University, 26 rue d'Ulm, Paris 75005, France
| | - Joanna Cyrta
- From the Departments of Radiology (T.R., C.T., C.M., A.T.), Medical Oncology (P.V.), Diagnostic and Theranostic Medicine - Pathology (J.C.), and Surgical Oncology (N.G.), Institut Curie, PSL Research University, 26 rue d'Ulm, Paris 75005, France
| | - Noémie Girard
- From the Departments of Radiology (T.R., C.T., C.M., A.T.), Medical Oncology (P.V.), Diagnostic and Theranostic Medicine - Pathology (J.C.), and Surgical Oncology (N.G.), Institut Curie, PSL Research University, 26 rue d'Ulm, Paris 75005, France
| | - Caroline Malhaire
- From the Departments of Radiology (T.R., C.T., C.M., A.T.), Medical Oncology (P.V.), Diagnostic and Theranostic Medicine - Pathology (J.C.), and Surgical Oncology (N.G.), Institut Curie, PSL Research University, 26 rue d'Ulm, Paris 75005, France
| | - Anne Tardivon
- From the Departments of Radiology (T.R., C.T., C.M., A.T.), Medical Oncology (P.V.), Diagnostic and Theranostic Medicine - Pathology (J.C.), and Surgical Oncology (N.G.), Institut Curie, PSL Research University, 26 rue d'Ulm, Paris 75005, France
| |
Collapse
|
12
|
Martin MJS, Frouin F, Malhaire C, Orlhac F. Decrypting the information captured by MRI-radiomic features in predicting the response to neoadjuvant chemotherapy in breast cancer. Annu Int Conf IEEE Eng Med Biol Soc 2022; 2022:3227-3230. [PMID: 36085726 DOI: 10.1109/embc48229.2022.9871844] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/15/2023]
Abstract
MRI-based radiomic models have shown promises in predicting the response to neoadjuvant chemotherapy in breast cancer. However, it is difficult to determine which information from the images contributes the most to the prediction: the distribution of gray-levels, the tumour heterogeneity, the shape of the lesions or the intensities of peritumoural regions. The purpose of this study is to dissociate the different sources of information to improve prediction results. Based on pre-treatment MR images from 103 patients, four types of 3D Volumes Of Interest were defined and arranged in multiple combinations. Combining features extracted from different regions proved to increase prediction performances. Clinical relevance- This study proposes a method based on analyses of MRI tumor heterogeneity, margins and peritumoral regions to improve the prediction of the response to neoadjuvant chemotherapy in breast cancer, which would help personalize patient treatment.
Collapse
|
13
|
El Beheiry M, Gaillard T, Girard N, Darrigues L, Osdoit M, Feron JG, Sabaila A, Laas E, Fourchotte V, Laki F, Lecuru F, Couturaud B, Binder JP, Masson JB, Reyal F, Malhaire C. Breast Magnetic Resonance Image Analysis for Surgeons Using Virtual Reality: A Comparative Study. JCO Clin Cancer Inform 2021; 5:1127-1133. [PMID: 34767435 DOI: 10.1200/cci.21.00048] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/24/2022] Open
Abstract
PURPOSE The treatment of breast cancer, the leading cause of cancer and cancer mortality among women worldwide, is mainly on the basis of surgery. In this study, we describe the use of a medical image visualization tool on the basis of virtual reality (VR), entitled DIVA, in the context of breast cancer tumor localization among surgeons. The aim of this study was to evaluate the speed and accuracy of surgeons using DIVA for medical image analysis of breast magnetic resonance image (MRI) scans relative to standard image slice-based visualization tools. MATERIALS AND METHODS In our study, residents and practicing surgeons used two breast MRI reading modalities: the common slice-based radiology interface and the DIVA system in its VR mode. Metrics measured were compared in relation to postoperative anatomical-pathologic reports. RESULTS Eighteen breast surgeons from the Institut Curie performed all the analysis presented. The MRI analysis time was significantly lower with the DIVA system than with the slice-based visualization for residents, practitioners, and subsequently the entire group (P < .001). The accuracy of determination of which breast contained the lesion significantly increased with DIVA for residents (P = .003) and practitioners (P = .04). There was little difference between the DIVA and slice-based visualization for the determination of the number of lesions. The accuracy of quadrant determination was significantly improved by DIVA for practicing surgeons (P = .01) but not significantly for residents (P = .49). CONCLUSION This study indicates that the VR visualization of medical images systematically improves surgeons' analysis of preoperative breast MRI scans across several different metrics irrespective of surgeon seniority.
Collapse
Affiliation(s)
- Mohamed El Beheiry
- Decision and Bayesian Computation, USR 3756 (C3BI/DBC) and Neuroscience Department CNRS UMR 3571, Institut Pasteur and CNRS, Paris, France
| | - Thomas Gaillard
- Surgery Department, Institut Curie, PSL Research University, Paris, France
| | - Noémie Girard
- Surgery Department, Institut Curie, PSL Research University, Paris, France
| | - Lauren Darrigues
- Surgery Department, Institut Curie, PSL Research University, Paris, France
| | - Marie Osdoit
- Surgery Department, Institut Curie, PSL Research University, Paris, France
| | | | - Anne Sabaila
- Surgery Department, Institut Curie, PSL Research University, Paris, France
| | - Enora Laas
- Surgery Department, Institut Curie, PSL Research University, Paris, France
| | | | - Fatima Laki
- Surgery Department, Institut Curie, PSL Research University, Paris, France
| | - Fabrice Lecuru
- Surgery Department, Institut Curie, PSL Research University, Paris, France
| | - Benoit Couturaud
- Surgery Department, Institut Curie, PSL Research University, Paris, France
| | | | - Jean-Baptiste Masson
- Decision and Bayesian Computation, USR 3756 (C3BI/DBC) and Neuroscience Department CNRS UMR 3571, Institut Pasteur and CNRS, Paris, France
| | - Fabien Reyal
- Surgery Department, Institut Curie, PSL Research University, Paris, France.,U932, Immunity and Cancer, INSERM, Institut Curie, Paris, France
| | - Caroline Malhaire
- Department of Medical Imaging, Institut Curie, PSL Research University, Paris, France.,Institut Curie, INSERM, LITO Laboratory, Orsay, France
| |
Collapse
|
14
|
El Sanharawi I, Bataillon G, Journo G, Farkhondeh F, Sebbag-Sfez D, Malhaire C, Tardivon A, Mosseri V, Thibault FE. Clinical management of atypical ductal hyperplasia on vacuum-assisted biopsy of microcalcifications: External validation study of a decision tree selecting patients eligible for surveillance. Eur J Radiol 2021; 141:109826. [PMID: 34174485 DOI: 10.1016/j.ejrad.2021.109826] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/02/2021] [Revised: 05/31/2021] [Accepted: 06/14/2021] [Indexed: 10/21/2022]
Abstract
BACKGROUND Atypical lesions found on percutaneous breast biopsy raise specific management issues. The aim of this study was to validate the previous performance of a decision tree defined by Forgeard et al to select a subset of patients at low-risk of surgical diagnostic upgrade that would be eligible for surveillance. METHODS A consecutive series of 211 patients diagnosed with ADH on vacuum-assisted biopsy (VAB) of clustered microcalcifications alone, then operated in our institution, was reviewed. Histological findings on percutaneous cores were compared with definitive diagnoses on surgical specimens. The rate of cancer underestimation on VAB was analyzed in the four arms and two management attitudes defined in the scheme, using size and quality of microcalcification removal and the number of ADH foci. RESULTS Ninety-eight women with ADH met the inclusion criteria. Overall, 20 cancers were diagnosed at surgery, showing a malignancy rate of 44% (17/39 patients) in the surgery group and of 5% (3/59 patients) in the surveillance group, which was not significantly different from the 2% rate in the monitored reference group (p > 0.64). The malignancy rate increased significantly with the size of clustered microcalcifications (0% when < 6mm, 17% when between 6mm and 21 mm, 48% when > 21 mm, p < 0001) and the number of ADH foci on VAB (14% when ≤ 2, 45% when > 2, p < 0.005). CONCLUSION Our results corroborate - within the limits of large confidence intervals - those obtained with the reference decision tree. Due to statistical uncertainty, however, they need to be prospectively validated in a broader series.
Collapse
Affiliation(s)
- Imane El Sanharawi
- Département d'Imagerie Médicale, Institut Curie, 26 rue d'Ulm, F-75005, Paris, France
| | - Guillaume Bataillon
- Pôle de Médecine Diagnostique et Théranostique, Institut Curie, 26 rue d'Ulm, F-75005, Paris, France
| | - Gabrielle Journo
- Département d'Imagerie Médicale, Institut Curie, 35 rue Dailly, F-92210, Saint-Cloud, France
| | - Fereshteh Farkhondeh
- Pôle de Médecine Diagnostique et Théranostique, Institut Curie, 26 rue d'Ulm, F-75005, Paris, France
| | - Delphine Sebbag-Sfez
- Département d'Imagerie Médicale, Institut Curie, 26 rue d'Ulm, F-75005, Paris, France
| | - Caroline Malhaire
- Département d'Imagerie Médicale, Institut Curie, 26 rue d'Ulm, F-75005, Paris, France; Laboratoire d'Imagerie Translationnelle en Oncologie, INSERM, Institut Curie, 91401, Orsay, France
| | - Anne Tardivon
- Département d'Imagerie Médicale, Institut Curie, 26 rue d'Ulm, F-75005, Paris, France
| | - Véronique Mosseri
- PSL Research University, DRCI, Biométrie, 35 Rue Dailly, F-92210, Saint-Cloud, France
| | - Fabienne E Thibault
- Département d'Imagerie Médicale, Institut Curie, 26 rue d'Ulm, F-75005, Paris, France.
| |
Collapse
|
15
|
Abstract
Oncoplastic surgery allows an increase in the number of indications for conservative breast cancer treatments. However, uncertainty as to whether it can be performed still exists in certain situations such as with multicentric or multifocal lesions, even when the breast volume can accommodate it. With the aid of a virtual reality software, DIVA, allowing the precise visualisation of tumours and breast volumes based entirely on the patient's MRI, we report the ability to rapidly confirm and secure an indication for partial surgery of multiple lesions in a 31-year-old patient. With the described approach, the patient did not have to suffer significant disfigurement from cancerous breast surgery without compromising safety.
Collapse
Affiliation(s)
- Enora Laas
- Surgery Department, Institut Curie, Paris, France
| | - Mohamed El Beheiry
- Decision and Bayesian Computation, Neuroscience Department, CNRS UMR 3571, Institut Pasteur, Paris, France .,Decision and Bayesian Computation, Computational Biology Department, CNRS USR 3756, Institut Pasteur, Paris, France
| | - Jean-Baptiste Masson
- Decision and Bayesian Computation, Neuroscience Department, CNRS UMR 3571, Institut Pasteur, Paris, France .,Decision and Bayesian Computation, Computational Biology Department, CNRS USR 3756, Institut Pasteur, Paris, France
| | | |
Collapse
|
16
|
Saint Martin MJ, Orlhac F, Akl P, Khalid F, Nioche C, Buvat I, Malhaire C, Frouin F. A radiomics pipeline dedicated to Breast MRI: validation on a multi-scanner phantom study. MAGMA 2020; 34:355-366. [PMID: 33180226 DOI: 10.1007/s10334-020-00892-y] [Citation(s) in RCA: 19] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 06/16/2020] [Revised: 09/27/2020] [Accepted: 10/23/2020] [Indexed: 12/14/2022]
Abstract
OBJECTIVE Quantitative analysis in MRI is challenging due to variabilities in intensity distributions across patients, acquisitions and scanners and suffers from bias field inhomogeneity. Radiomic studies are impacted by these effects that affect radiomic feature values. This paper describes a dedicated pipeline to increase reproducibility in breast MRI radiomic studies. MATERIALS AND METHODS T1, T2, and T1-DCE MR images of two breast phantoms were acquired using two scanners and three dual breast coils. Images were retrospectively corrected for bias field inhomogeneity and further normalised using Z score or histogram matching. Extracted radiomic features were harmonised between coils by the ComBat method. The whole pipeline was assessed qualitatively and quantitatively using statistical comparisons on two series of radiomic feature values computed in the gel mimicking the normal breast tissue or in dense lesions. RESULTS Intra and inter-acquisition variabilities were strongly reduced by the standardisation pipeline. Harmonisation by ComBat lowered the percentage of radiomic features significantly different between the three coils from 87% after bias field correction and MR normalisation to 3% in the gel, while preserving or improving performance of lesion classification in the phantoms. DISCUSSION A dedicated standardisation pipeline was developed to reduce variabilities in breast MRI, which paves the way for robust multi-scanner radiomic studies but needs to be assessed on patient data.
Collapse
Affiliation(s)
- Marie-Judith Saint Martin
- Inserm, Institut Curie,Université Paris-Saclay, Laboratoire d'Imagerie Translationnelle en Oncologie (LITO), Centre de Recherche de l'Institut Curie, Bât 101B rue Henri Becquerel, 91401, Orsay, France.
| | - Fanny Orlhac
- Inserm, Institut Curie,Université Paris-Saclay, Laboratoire d'Imagerie Translationnelle en Oncologie (LITO), Centre de Recherche de l'Institut Curie, Bât 101B rue Henri Becquerel, 91401, Orsay, France
| | - Pia Akl
- Inserm, Institut Curie,Université Paris-Saclay, Laboratoire d'Imagerie Translationnelle en Oncologie (LITO), Centre de Recherche de l'Institut Curie, Bât 101B rue Henri Becquerel, 91401, Orsay, France
- HCL, Radiologie du Groupement Hospitalier Est, Hôpital Femme Mère Enfant, Unité Fonctionnelle: Imagerie de la Femme, 3 Quai des Célestins, 69002, Lyon, France
- Institut Curie, Service de Radiodiagnostic, 26 rue d'Ulm, 75005, Paris, France
| | - Fahad Khalid
- Inserm, Institut Curie,Université Paris-Saclay, Laboratoire d'Imagerie Translationnelle en Oncologie (LITO), Centre de Recherche de l'Institut Curie, Bât 101B rue Henri Becquerel, 91401, Orsay, France
| | - Christophe Nioche
- Inserm, Institut Curie,Université Paris-Saclay, Laboratoire d'Imagerie Translationnelle en Oncologie (LITO), Centre de Recherche de l'Institut Curie, Bât 101B rue Henri Becquerel, 91401, Orsay, France
| | - Irène Buvat
- Inserm, Institut Curie,Université Paris-Saclay, Laboratoire d'Imagerie Translationnelle en Oncologie (LITO), Centre de Recherche de l'Institut Curie, Bât 101B rue Henri Becquerel, 91401, Orsay, France
| | - Caroline Malhaire
- Inserm, Institut Curie,Université Paris-Saclay, Laboratoire d'Imagerie Translationnelle en Oncologie (LITO), Centre de Recherche de l'Institut Curie, Bât 101B rue Henri Becquerel, 91401, Orsay, France
- Institut Curie, Service de Radiodiagnostic, 26 rue d'Ulm, 75005, Paris, France
| | - Frédérique Frouin
- Inserm, Institut Curie,Université Paris-Saclay, Laboratoire d'Imagerie Translationnelle en Oncologie (LITO), Centre de Recherche de l'Institut Curie, Bât 101B rue Henri Becquerel, 91401, Orsay, France
| |
Collapse
|
17
|
Thomassin-Naggara I, Poncelet E, Jalaguier-Coudray A, Guerra A, Fournier LS, Stojanovic S, Millet I, Bharwani N, Juhan V, Cunha TM, Masselli G, Balleyguier C, Malhaire C, Perrot NF, Sadowski EA, Bazot M, Taourel P, Porcher R, Darai E, Reinhold C, Rockall AG. Ovarian-Adnexal Reporting Data System Magnetic Resonance Imaging (O-RADS MRI) Score for Risk Stratification of Sonographically Indeterminate Adnexal Masses. JAMA Netw Open 2020; 3:e1919896. [PMID: 31977064 PMCID: PMC6991280 DOI: 10.1001/jamanetworkopen.2019.19896] [Citation(s) in RCA: 124] [Impact Index Per Article: 31.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/16/2022] Open
Abstract
IMPORTANCE Approximately one-quarter of adnexal masses detected at ultrasonography are indeterminate for benignity or malignancy, posing a substantial clinical dilemma. OBJECTIVE To validate the accuracy of a 5-point Ovarian-Adnexal Reporting Data System Magnetic Resonance Imaging (O-RADS MRI) score for risk stratification of adnexal masses. DESIGN, SETTING, AND PARTICIPANTS This multicenter cohort study was conducted between March 1, 2013, and March 31, 2016. Among patients undergoing expectant management, 2-year follow-up data were completed by March 31, 2018. A routine pelvic MRI was performed among consecutive patients referred to characterize a sonographically indeterminate adnexal mass according to routine diagnostic practice at 15 referral centers. The MRI score was prospectively applied by 2 onsite readers and by 1 reader masked to clinical and ultrasonographic data. Data analysis was conducted between April and November 2018. MAIN OUTCOMES AND MEASURES The primary end point was the joint analysis of true-negative and false-negative rates according to the MRI score compared with the reference standard (ie, histology or 2-year follow-up). RESULTS A total of 1340 women (mean [range] age, 49 [18-96] years) were enrolled. Of 1194 evaluable women, 1130 (94.6%) had a pelvic mass on MRI with a reference standard (surgery, 768 [67.9%]; 2-year follow-up, 362 [32.1%]). A total of 203 patients (18.0%) had at least 1 malignant adnexal or nonadnexal pelvic mass. No invasive cancer was assigned a score of 2. Positive likelihood ratios were 0.01 for score 2, 0.27 for score 3, 4.42 for score 4, and 38.81 for score 5. Area under the receiver operating characteristic curve was 0.961 (95% CI, 0.948-0.971) among experienced readers, with a sensitivity of 0.93 (95% CI, 0.89-0.96; 189 of 203 patients) and a specificity of 0.91 (95% CI, 0.89-0.93; 848 of 927 patients). There was good interrater agreement among both experienced and junior readers (κ = 0.784; 95% CI, 0.743-0824). Of 580 of 1130 women (51.3%) with a mass on MRI and no specific gynecological symptoms, 362 (62.4%) underwent surgery. Of them, 244 (67.4%) had benign lesions and a score of 3 or less. The MRI score correctly reclassified the mass origin as nonadnexal with a sensitivity of 0.99 (95% CI, 0.98-0.99; 1360 of 1372 patients) and a specificity of 0.78 (95% CI, 0.71-0.85; 102 of 130 patients). CONCLUSIONS AND RELEVANCE In this study, the O-RADS MRI score was accurate when stratifying the risk of malignancy in adnexal masses.
Collapse
Affiliation(s)
- Isabelle Thomassin-Naggara
- Service de Radiologie, Hôpital Tenon, Assistance Publique–Hôpitaux de Paris, Sorbonne Université, Paris, France
- Institute for Computing and Data Sciences, Sorbonne Université, Paris, France
- American College of Radiology, Ovarian-Adnexal Reporting and Data System Magnetic Resonance Imaging Committee
| | - Edouard Poncelet
- Service d’Imagerie de la Femme, Centre Hospitalier de Valenciennes, Valenciennes, France
| | | | | | - Laure S. Fournier
- Department of Radiology, Hôpital Européen Georges Pompidou, Assistance Publique-Hôpitaux de Paris, Université Paris-Descartes, Paris, France
| | - Sanja Stojanovic
- Centre for Radiology, Clinical Centre of Vojvodina, Medical Faculty, University of Novi Sad, Novi Sad, Serbia and Montenegro
| | - Ingrid Millet
- Lapeyronie Hospital, University of Montpellier, Montpellier, France
| | - Nishat Bharwani
- Department of Radiology, Imperial College Healthcare NHS Trust, London, United Kingdom
| | | | - Teresa M. Cunha
- Department of Radiology, Instituto Português de Oncologia de Lisboa Francisco Gentil, Lisboa, Portugal
| | - Gabriele Masselli
- Department of Radiology, Umberto I Hospital, Sapienza University Roma, Rome, Italy
| | | | | | | | - Elizabeth A. Sadowski
- American College of Radiology, Ovarian-Adnexal Reporting and Data System Magnetic Resonance Imaging Committee
- University of Wisconsin, Madison, Wisconsin
| | - Marc Bazot
- Service de Radiologie, Hôpital Tenon, Assistance Publique–Hôpitaux de Paris, Sorbonne Université, Paris, France
- Institute for Computing and Data Sciences, Sorbonne Université, Paris, France
| | - Patrice Taourel
- Lapeyronie Hospital, University of Montpellier, Montpellier, France
| | - Raphaël Porcher
- Centre of Research in Epidemiology and Statistics Sorbonne Paris Cité, Institute national de la santé et de la recherche médicale, Joint Research Unit 1153, Paris, France
| | - Emile Darai
- Service de Gynecologie et Obstetrique et Médecine de la Reproduction, Hôpital Tenon, Assistance Publique–Hôpitaux de Paris, Hôpitaux Univesitaires Est Parisien, Paris, France
- Faculté de Médecine Pierre et Marie Curie, Sorbonne Université, Paris, France
| | - Caroline Reinhold
- American College of Radiology, Ovarian-Adnexal Reporting and Data System Magnetic Resonance Imaging Committee
- Department of Medical Imaging, McGill University Health Centre, Montreal, Quebec, Canada
| | - Andrea G. Rockall
- American College of Radiology, Ovarian-Adnexal Reporting and Data System Magnetic Resonance Imaging Committee
- Department of Radiology, Imperial College Healthcare NHS Trust, London, United Kingdom
- Division of Cancer and Surgery, Faculty of Medicine, Imperial College London, United Kingdom
| |
Collapse
|
18
|
Girard N, Delomenie M, Malhaire C, Sebbag D, Roulot A, Sabaila A, Couturaud B, Feron JG, Reyal F. Innovative DIEP flap perfusion evaluation tool: Qualitative and quantitative analysis of indocyanine green-based fluorescence angiography with the SPY-Q proprietary software. PLoS One 2019; 14:e0217698. [PMID: 31237884 PMCID: PMC6592538 DOI: 10.1371/journal.pone.0217698] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/19/2018] [Accepted: 05/16/2019] [Indexed: 11/17/2022] Open
Abstract
BACKGROUND Perfusion-related complications remain the most common concern in DIEP flap breast reconstruction. Indocyanine green-based fluorescence angiography can be used for the real-time intra operative assessment of flap perfusion. The SPY Elite system is the most widely used device in this setting. The main objective was to describe the use of SPY-Q proprietary software to perform qualitative and quantitative analysis of flap perfusion. METHODS This retrospective cohort study was performed at the Curie Institute between 2013 and 2017. We included patients undergoing unilateral DIEP flap breast reconstruction for whom indocyanine green-based angiography videos were of sufficient quality for analysis. Videos were recorded with the SPY Elite System and analyzed with SPY-Q proprietary software. RESULTS We included 40 patients. We used real-time dynamic color analysis to describe three different patterns of flap perfusion. SPY-Q proprietary software provides quantitative flap perfusion parameters. Our quantitative analysis confirmed that zone I is the best perfused part of the flap and zone IV the less perfused one. There was no significant association between flap perfusion pattern and perforator anatomy, patients' clinical characteristics or postoperative outcomes. After exploratory univariate analysis, quantitative perfusion parameters were significantly impaired in young patients with diabetes mellitus or under hormone therapy by tamoxifen. CONCLUSIONS We here describe a new approach to assess DIEP flap perfusion using the SPY Elite System proprietary software. It provides interesting qualitative and quantitative analysis that can be used in further studies to precisely assess DIEP flap perfusion.
Collapse
Affiliation(s)
- Noémie Girard
- Department of Gynecological and Breast Oncological Surgery, Curie Institute, Paris, France
| | - Myriam Delomenie
- Department of Gynecological and Breast Oncological Surgery, Curie Institute, Paris, France
| | | | | | - Aurélie Roulot
- Department of Gynecological and Breast Oncological Surgery, Curie Institute, Paris, France
| | - Anne Sabaila
- Department of Gynecological and Breast Oncological Surgery, Curie Institute, Paris, France
| | - Benoît Couturaud
- Department of Plastic and Reconstructive Surgery, Curie Institute, Paris, France
| | - Jean-Guillaume Feron
- Department of Gynecological and Breast Oncological Surgery, Curie Institute, Paris, France
| | - Fabien Reyal
- Department of Gynecological and Breast Oncological Surgery, Curie Institute, Paris, France.,Université de Paris, Université Paris Descartes, Paris, France
| |
Collapse
|
19
|
Lassau N, Estienne T, de Vomecourt P, Azoulay M, Cagnol J, Garcia G, Majer M, Jehanno E, Renard-Penna R, Balleyguier C, Bidault F, Caramella C, Jacques T, Dubrulle F, Behr J, Poussange N, Bocquet J, Montagne S, Cornelis F, Faruch M, Bresson B, Brunelle S, Jalaguier-Coudray A, Amoretti N, Blum A, Paisant A, Herreros V, Rouviere O, Si-Mohamed S, Di Marco L, Hauger O, Garetier M, Pigneur F, Bergère A, Cyteval C, Fournier L, Malhaire C, Drape JL, Poncelet E, Bordonne C, Cauliez H, Budzik JF, Boisserie M, Willaume T, Molière S, Peyron Faure N, Caius Giurca S, Juhan V, Caramella T, Perrey A, Desmots F, Faivre-Pierre M, Abitbol M, Lotte R, Istrati D, Guenoun D, Luciani A, Zins M, Meder JF, Cotten A. Five simultaneous artificial intelligence data challenges on ultrasound, CT, and MRI. Diagn Interv Imaging 2019; 100:199-209. [DOI: 10.1016/j.diii.2019.02.001] [Citation(s) in RCA: 22] [Impact Index Per Article: 4.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/17/2019] [Accepted: 02/04/2019] [Indexed: 12/18/2022]
|
20
|
Rageth CJ, O'Flynn EAM, Pinker K, Kubik-Huch RA, Mundinger A, Decker T, Tausch C, Dammann F, Baltzer PA, Fallenberg EM, Foschini MP, Dellas S, Knauer M, Malhaire C, Sonnenschein M, Boos A, Morris E, Varga Z. Second International Consensus Conference on lesions of uncertain malignant potential in the breast (B3 lesions). Breast Cancer Res Treat 2018; 174:279-296. [PMID: 30506111 PMCID: PMC6538569 DOI: 10.1007/s10549-018-05071-1] [Citation(s) in RCA: 146] [Impact Index Per Article: 24.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/21/2018] [Accepted: 11/23/2018] [Indexed: 11/24/2022]
Abstract
Purpose The second International Consensus Conference on B3 lesions was held in Zurich, Switzerland, in March 2018, organized by the International Breast Ultrasound School to re-evaluate the consensus recommendations. Methods This study (1) evaluated how management recommendations of the first Zurich Consensus Conference of 2016 on B3 lesions had influenced daily practice and (2) reviewed current literature towards recommendations to biopsy. Results In 2018, the consensus recommendations for management of B3 lesions remained almost unchanged: For flat epithelial atypia (FEA), classical lobular neoplasia (LN), papillary lesions (PL) and radial scars (RS) diagnosed on core-needle biopsy (CNB) or vacuum-assisted biopsy (VAB), excision by VAB in preference to open surgery, and for atypical ductal hyperplasia (ADH) and phyllodes tumors (PT) diagnosed at VAB or CNB, first-line open surgical excision (OE) with follow-up surveillance imaging for 5 years. Analyzing the Database of the Swiss Minimally Invasive Breast Biopsies (MIBB) with more than 30,000 procedures recorded, there was a significant increase in recommending more frequent surveillance of LN [65% in 2018 vs. 51% in 2016 (p = 0.004)], FEA (72% in 2018 vs. 62% in 2016 (p = 0.005)), and PL [(76% in 2018 vs. 70% in 2016 (p = 0.04)] diagnosed on VAB. A trend to more frequent surveillance was also noted also for RS [77% in 2018 vs. 67% in 2016 (p = 0.07)]. Conclusions Minimally invasive management of B3 lesions (except ADH and PT) with VAB continues to be appropriate as an alternative to first-line OE in most cases, but with more frequent surveillance, especially for LN.
Collapse
Affiliation(s)
- Christoph J Rageth
- Département de Gynécologie et d'Obstétrique, Centre du sein, Hôpitaux Universitaires de Genève, Bd de la Cluse 30, 1211, Geneva 14, Switzerland. .,, Ringlikerstrasse 53, 8142, Uitikon Waldegg, Switzerland.
| | - Elizabeth A M O'Flynn
- The Rose Centre, St George's University Hospitals NHS Foundation Trust, Perimeter Road, London, SW17 0QT, UK
| | - Katja Pinker
- Breast Imaging Service, Department of Radiology, Memorial Sloan Kettering Cancer Center, 300 E 66th St, New York, NY, 10065, USA
| | - Rahel A Kubik-Huch
- Department of Medical Services, Institute of Radiology, Kantonsspital Baden, im Ergel, 5404, Baden, Switzerland
| | - Alexander Mundinger
- Zentrum Radiologie der Niels-Stensen-Kliniken; Marienhospital Osnabrück, Bischofsstraße 1, 49074, Osnabrück, Germany
| | - Thomas Decker
- Institut für Pathologie am Dietrich-Bonhoeffer-Klinikum, Salvador-Allende-Straße 30, 17036, Neubrandenburg, Germany
| | - Christoph Tausch
- Brust-Zentrum Zürich, Seefeldstr. 214, 8008, Zurich, Switzerland
| | - Florian Dammann
- Interventional and Pediatric Radiology, Department of Diagnostic, Inselspital, University Hospital Bern, Freiburgstrasse 10, 3010, Bern, Switzerland
| | - Pascal A Baltzer
- Department of Biomedical Imaging and Image-guided Therapy, Allgemeines Krankenhaus, Medical University of Vienna, Währinger Gürtel 18-20, 1090, Vienna, Austria
| | - Eva Maria Fallenberg
- Department of Radiology, University Hospital, Ludwig Maximilian University Munich, Marchioninistr. 15, 81377, Munich, Germany
| | - Maria P Foschini
- Department of Biomedical and Neuromotor Sciences, Unit of Anatomic Pathology at Bellaria Hospital, University of Bologna, Via Altura 3, 40139, Bologna, Italy
| | - Sophie Dellas
- Clinic of Radiology and Nuclear Medicine, University Hospital Basel, University of Basel, Petersgraben 4, 4031, Basel, Switzerland
| | - Michael Knauer
- Breast Center St. Gallen, Cantonal Hospital St. Gallen, Rorschacher Str. 95, 9007, St. Gallen, Switzerland
| | - Caroline Malhaire
- Imaging Department, Institut Curie, PSL Research University, Paris, France
| | - Martin Sonnenschein
- Division of Radiology, Breast Center Bern (Brustzentrum Bern), Klinik Engeried, Lindenhofgruppe AG, Riedweg 15, 3012, Bern, Switzerland
| | - Andreas Boos
- Institute of Diagnostic and Interventional Radiology, University Hospital Zurich, Rämistr. 100, 8091, Zurich, Switzerland
| | - Elisabeth Morris
- Breast Imaging Service, Department of Radiology, Memorial Sloan Kettering Cancer Center, 300 E 66th St, New York, NY, 10065, USA
| | - Zsuzsanna Varga
- Institute of Pathology and Molecular Pathology, University Hospital Zurich, Switzerland Schmelzbergstrasse 12., 8091, Zurich, Switzerland
| |
Collapse
|
21
|
Bermot C, Saint-Martin C, Malhaire C, Sebbag-Sfez D, Mouret-Fourme E, Carton M, Thibault FE. Background parenchymal enhancement and fibroglandular tissue on breast MRI in women with high genetic risk: Are changes before and after risk-reducing salpingo-oophorectomy associated with breast cancer risk? Eur J Radiol 2018; 109:171-177. [PMID: 30527300 DOI: 10.1016/j.ejrad.2018.10.030] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/12/2018] [Revised: 09/25/2018] [Accepted: 10/30/2018] [Indexed: 02/05/2023]
Abstract
BACKGROUND Parenchymal enhancement and fibroglandular tissue on breast MRI in women with high genetic risk: are changes before and after risk-reducing salpingo-oophorectomy associated with breast cancer risk? OBJECTIVE To evaluate changes in the level of background parenchymal enhancement (BPE) and amount of fibroglandular tissue (FGT) on breast MRI before and after risk-reducing oophorectomy (RRSO), and to determine whether these changes correlate with ultimate breast cancer risk. MATERIALS AND METHODS The cohort included 146 women with high genetic risk who had undergone pre- and post-RRSO breast MRI. BPE level and FGT amount were retrospectively graded according to BI-RADS classification. Initial values and changes were compared in women with or without later breast cancer after RRSO. Hazard ratios (HR) were estimated using Cox univariate models. RESULTS Patients with initial moderate (BI-RADS C category) BPE had a higher risk of subsequent breast cancer of HR = 3.9 (95% CI [1.1-14.3]; p = 0.04) compared to patients with initial minimal (BI-RADS A) BPE. A categorical BPE decrease after RRSO, versus no change, was associated with a higher cancer risk (HR 2.2, 95% CI [1.04-4.8]; p = 0.04). Initially dense (BI-RADS 3 category) FGT correlated with an increased cancer risk compared to fatty (BI-RADS 1 category) parenchyma (HR 8.3, 95% CI [1.1-64]; p = 0.04). After RRSO, there was a trend for higher cancer risk related to a categorical FGT decrease (HR 2.3, 95% CI [0.9-35.4]; p = 0.06). CONCLUSION Patients in whom BPE decreases after RRSO might be at higher risk of subsequent breast cancer compared to patients with stable BPE. This finding is consistent with the concept of increased risk associated with high initial BPE, which could be of higher clinical relevance than post-RRSO BPE reduction. A similar trend was observed with high initial FGT.
Collapse
Affiliation(s)
- Cécile Bermot
- Institut Curie, Département d'Imagerie Médicale, 26 rue d'Ulm, F-75005 Paris, France.
| | - Caroline Saint-Martin
- Institut Curie, PSL Research University, DRCI, Biométrie, 35 Rue Dailly, F-92210, Saint-Cloud, France.
| | - Caroline Malhaire
- Institut Curie, Département d'Imagerie Médicale, 26 rue d'Ulm, F-75005 Paris, France
| | - Delphine Sebbag-Sfez
- Institut Curie, Département d'Imagerie Médicale, 26 rue d'Ulm, F-75005 Paris, France.
| | | | - Matthieu Carton
- Institut Curie, PSL Research University, DRCI, Biométrie, 35 Rue Dailly, F-92210, Saint-Cloud, France.
| | - Fabienne E Thibault
- Institut Curie, Département d'Imagerie Médicale, 26 rue d'Ulm, F-75005 Paris, France.
| |
Collapse
|
22
|
Haioun C, Laurent C, Le Bras F, Dao TH, Itti E, Malhaire C, Chopier J, Sinna R, Kirova Y, Bachy E, Slama B, Schiano JM, Bannier M, Traverse-Glehen A, Bosc R, Xerri L, Reyal F, Tilly H, Gaulard P. Breast Implant Associated-Anaplastic Large Cell Lymphoma (BIA-ALCL): The French Lymphoma Study Association (LYSA) registry data. J Clin Oncol 2018. [DOI: 10.1200/jco.2018.36.15_suppl.7554] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
| | | | | | | | | | | | | | | | | | - Emmanuel Bachy
- Hospices Civils de Lyon-Hôpital Lyon Sud, Pierre-Bénite, France
| | | | | | | | | | | | - Luc Xerri
- Institut Paoli-Calmettes, Marseille, France
| | | | - Herve Tilly
- Centre Henri Becquerel, University of Rouen, Rouen, France
| | | |
Collapse
|
23
|
Journo G, Bataillon G, Benchimol R, Bekhouche A, Dratwa C, Sebbag-Sfez D, Tardivon A, Thibault F, Ala-Eddine C, Chérel P, Malhaire C. Hyperechoic breast images: all that glitters is not gold! Insights Imaging 2018; 9:199-209. [PMID: 29476429 PMCID: PMC5893486 DOI: 10.1007/s13244-017-0590-1] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/20/2017] [Revised: 12/07/2017] [Accepted: 12/27/2017] [Indexed: 11/27/2022] Open
Abstract
Abstract Hyperechogenicity is a sign classically reported to be in favour of a benign lesion and can be observed in many types of benign breast lesions such as hamartoma, lipoma, angiolipoma, haemangioma, haematoma, fat necrosis, fibrosis and galactocele, among others. However, some rare malignant breast lesions can also present a hyperechoic appearance. Most of these hyperechoic malignant lesions present other characteristics that are more typically suggestive of malignancy such as posterior shadowing, a more vertical axis or irregular margins that help to guide the diagnosis. Post magnetic resonance imaging, second-look ultrasound may visualise hyperechoic malignant lesions that would not have been identified at first sight and radiologists must know how to recognise these lesions. Teaching Points • Some rare malignant breast lesions can present a hyperechoic appearance. • Malignant lesions present other characteristics that are suggestive of malignancy. • An echogenic mass with fat density on mammography does not require biopsy.
Collapse
Affiliation(s)
| | | | | | | | - Chloe Dratwa
- Institut Curie, 26 rue d'Ulm, 75005, Paris, France
| | | | | | | | | | - Pascal Chérel
- Centre René Huguenin, 35 rue Dailly, 92210, Saint-Cloud, France
| | | |
Collapse
|
24
|
Bazire L, Kirova Y, Xu H, Foy J, Malhaire C, Cao K, Rochefordiere ADL. Pelvic Insufficiency Fracture Incidence in Patients Treated With Intensity-Modulated Radiation Therapy for Gynecological or Anal Cancer. Int J Radiat Oncol Biol Phys 2017. [DOI: 10.1016/j.ijrobp.2017.06.1315] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
25
|
Bazire L, Xu H, Amessis M, Malhaire C, Cao K, De La Rochefordière A, Kirova Y. PO-0716: Pelvic insufficiency fracture after IMRT for gynecologic or anal cancer. Radiother Oncol 2017. [DOI: 10.1016/s0167-8140(17)31153-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
26
|
Bazire L, Xu H, Foy JP, Amessis M, Malhaire C, Cao K, De La Rochefordiere A, Kirova YM. Pelvic insufficiency fracture (PIF) incidence in patients treated with intensity-modulated radiation therapy (IMRT) for gynaecological or anal cancer: single-institution experience and review of the literature. Br J Radiol 2017; 90:20160885. [PMID: 28291401 DOI: 10.1259/bjr.20160885] [Citation(s) in RCA: 24] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/22/2022] Open
Abstract
OBJECTIVE To summarize the results of pelvic insufficiency fracture (PIF) incidence in patients with anal or gynaecological cancer treated by pelvic intensity-modulated radiation therapy (IMRT). METHODS The clinical and morphological (CT and/or pelvic MRI) characteristics of patients treated by IMRT at our institution between 2007 and 2014 were analyzed. The global incidence of PIF after external beam radiotherapy and the impact of tumour site (gynaecological or anal cancer) were determined. A dosimetric study was then performed to compare patients with and without pelvic fracture. RESULTS 341 patients were treated by IMRT for gynaecological or anal cancer between 2007 and 2014. 15 patients experienced at least 1 pelvic fracture after external beam radiotherapy, corresponding to an overall incidence of 4.4%. Age and menopausal status were correlated with an increased fracture risk (p = 0.0274 and p < 0.0001, respectively). The site of the primary tumour (gynaecological or anal canal) was not associated with an excess fracture risk. The median maximum dose received at the fracture site was 50.3 Gy (range: 40.8-68.4 Gy). CONCLUSION The incidence of pelvic fracture after IMRT is low, but is higher after the age of 50 and in patients who are postmenopausal. Pre-treatment evaluation of bone density by bone densitometry and phosphorus-calcium assessment could be useful prior to the management of these patients. Advances in knowledge: Pelvic fractures are a frequent complication after radiotherapy. The influence of IMRT and clinical characteristics were evaluated in this study.
Collapse
Affiliation(s)
- Louis Bazire
- Department of Radiation Oncology, Institut Curie, Paris, France
| | - Haoping Xu
- Department of Radiation Oncology, Institut Curie, Paris, France
| | | | - Malika Amessis
- Department of Radiation Oncology, Institut Curie, Paris, France
| | | | - Kim Cao
- Department of Radiation Oncology, Institut Curie, Paris, France
| | | | - Youlia M Kirova
- Department of Radiation Oncology, Institut Curie, Paris, France
| |
Collapse
|
27
|
Nguyen Ba E, Golfier F, Malhaire C, Louafi L, Alran S. [Placental site trophoblastic tumor: When do we suspect it and which treatment shall we decide?]. ACTA ACUST UNITED AC 2016; 45:979-984. [PMID: 27692520 DOI: 10.1016/j.jgyn.2016.04.003] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/05/2016] [Revised: 04/12/2016] [Accepted: 04/26/2016] [Indexed: 11/25/2022]
Abstract
Tumors of trophoblast implantation site TTSI are rare gestational tumors. This case highlights the diagnostic difficulties and treatment of tumors of trophoblastic implantation site early. Patient of 28 years with no medical history, G1P1 who gave birth 11 months ago presented bleeding with an HCG level of 73IU that led to the diagnosis of early miscarriage. Treatment of miscarriage by hysteroscopy and curettage is complicated leading to the realization of an abdominopelvic CT and pelvic ultrasound that show an atypical uterine vascularity and an intracavitary heterogeneous mass. The pelvic MRI performed evokes a TTSI stage I. A hysterectomy with bilateral salpingectomy and ovarian conservation is achieved. Despite the standard treatment with surgery the HCG levels do not normalize before seven months after surgery. This indicates an adjuvant chemotherapy, the patient refuses. The presented case illustrates the diagnostic difficulties of the disease. He noted the importance of the second reading network proposed by the specialized center in Lyon. It also raises the question of adjuvant chemotherapy in some cases of early stage TTSI. The challenge is to define cases requiring adjuvant therapy. Predictors of chemotherapy in early stages could be tumor size, degree of infiltration of the myometrium and mutation p53. Amenorrhea, bleeding associated with uterine atypical vascularization, and atypical development of HCG<1000IU and/or unusual complications of treatment of miscarriage should evoke a tumor site trophoblastic implantation. Hysterectomy is the first treatment in early stages. Tumor size, degree of infiltration of the myometrium and mutation p53 are predictors to assess in multicentre studies to define the indications of postoperative chemotherapy.
Collapse
Affiliation(s)
- E Nguyen Ba
- Institut Curie Paris, 26, rue d'Ulm, 75005 Paris, France.
| | - F Golfier
- Centre des maladies trophoblastiques de Lyon, centre hospitalier Lyon-Sud, 165, chemin du Grand-Revoyet, 69495 Pierre-Bénite, France.
| | - C Malhaire
- Institut Curie Paris, 26, rue d'Ulm, 75005 Paris, France.
| | - L Louafi
- Institut Curie Paris, 26, rue d'Ulm, 75005 Paris, France.
| | - S Alran
- Institut Curie Paris, 26, rue d'Ulm, 75005 Paris, France.
| |
Collapse
|
28
|
Bazire L, Dautruche A, Kirova Y, Cao K, Malhaire C, de La Rochefordiere A. Pelvic Insufficiency Fracture After Intensity Modulated Radiation Therapy for Gynecologic Cancer. Int J Radiat Oncol Biol Phys 2016. [DOI: 10.1016/j.ijrobp.2016.06.1392] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
29
|
Malhaire C, Hequet D, Falcou MC, Feron JG, Tardivon A, Leduey A, Guillot E, Mosseri V, Rouzier R, Couturaud B, Reyal F. Outcome of oncoplastic breast-conserving surgery following bracketing wire localization for large breast cancer. Breast 2015; 24:370-5. [PMID: 25913288 DOI: 10.1016/j.breast.2015.02.037] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/10/2014] [Revised: 02/16/2015] [Accepted: 02/22/2015] [Indexed: 12/23/2022] Open
Abstract
PURPOSE The purpose of this study was to evaluate the outcome of breast conserving surgery comparing oncoplastic surgery (OS) and standard lumpectomy (SL) after preoperative bracketing wire localization of large neoplastic lesions. METHODS We retrospectively reviewed the medical records and the mammograms of patients operated on at the Institut Curie between May 2005 and September 2011 after bracketing wire localization under mammographic and/or sonographic guidance. RESULTS 113 patients underwent surgery for a pre-operative diagnosis of DCIS (n = 80), micro-invasive carcinoma (n = 9) or invasive carcinoma (n = 24), by OS (n = 73) or SL (n = 40). In the OS group, radiological size (52 mm vs 39 mm, p < 0.001) and resection volumes (246 cc vs 88 cc, p < 0.00001) were significantly higher than in the SL group. Rates of clear histologic margins (60 vs 62%, NS), complete excision of microcalcifications (78% vs 72%, NS) and re-intervention rate (40% vs 42%, NS) were equivalent. The rate of local recurrence at 24 months was 3% [0-7.1] in patients with conservative treatment (n = 3). With a median follow-up of 40 months, 5 local relapses (two with axillary metastatic involvement), two distant metastatic evolution, one contralateral breast cancer and one death unrelated to cancer occurred. CONCLUSION Following bracketing wire localization, OS allowed the conserving management of significantly larger lesions with wider resection volumes, without significant increase in margin involvement or re-intervention rate, and equivalent rate of microcalcifications clearance compared to SL.
Collapse
Affiliation(s)
- Caroline Malhaire
- Department of Radiology, Institut Curie, 26 rue d'Ulm, 75005 Paris, France.
| | - Delphine Hequet
- Department of Surgical Oncology, Institut Curie, 26 rue d'Ulm, 75005 Paris, France
| | | | - Jean-Guillaume Feron
- Department of Surgical Oncology, Institut Curie, 26 rue d'Ulm, 75005 Paris, France
| | - Anne Tardivon
- Department of Radiology, Institut Curie, 26 rue d'Ulm, 75005 Paris, France
| | - Alexandre Leduey
- Department of Surgical Oncology, Institut Curie, 26 rue d'Ulm, 75005 Paris, France
| | - Eugénie Guillot
- Department of Surgical Oncology, Institut Curie, 26 rue d'Ulm, 75005 Paris, France
| | - Véronique Mosseri
- Department of Public Health, Institut Curie, 26 rue d'Ulm, 75005 Paris, France
| | - Roman Rouzier
- Department of Surgical Oncology, Institut Curie, 26 rue d'Ulm, 75005 Paris, France
| | - Benoit Couturaud
- Department of Surgical Oncology, Institut Curie, 26 rue d'Ulm, 75005 Paris, France
| | - Fabien Reyal
- Department of Surgical Oncology, Institut Curie, 26 rue d'Ulm, 75005 Paris, France
| |
Collapse
|
30
|
Ngô C, Brugier C, Plancher C, de la Rochefordière A, Alran S, Féron JG, Malhaire C, Scholl S, Sastre X, Rouzier R, Fourchotte V. Clinico-pathology and prognosis of endometrial cancer in patients previously treated for breast cancer, with or without tamoxifen: a comparative study in 363 patients. Eur J Surg Oncol 2014; 40:1237-44. [PMID: 25086993 DOI: 10.1016/j.ejso.2014.05.007] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/10/2014] [Revised: 05/13/2014] [Accepted: 05/15/2014] [Indexed: 01/13/2023] Open
Abstract
OBJECTIVE To compare the clinic-pathologic variables and the prognosis of endometrial cancer in patients with and without previous breast cancer, with and without Tamoxifen. METHODS We analyzed patients treated for an endometrial carcinoma from 1994 to 2004: patients without breast cancer (group 1), patients with a previous breast cancer without tamoxifen (group 2) and patients treated for breast cancer with tamoxifen (group 3). Survival rates were calculated according to Kaplan-Meier method and compared using a Log rank test, multivariate analysis was performed with a Cox regression model. RESULTS 363 patients were analyzed. 80 patients had a previous history of breast cancer (43 received tamoxifen). Although it was not statistically significant, more carcinosarcomas were observed in patients in group 3 than patients in groups 1 and 2 (11.7% versus 4.2% and 5.4% respectively, p = 0.17).) Median follow-up was 87 months [2-185]. 5-year overall survival rate was respectively in groups 1, 2 and 3: 82%, 73.2%, and 61% (p = 0.0006). 5-year local relapse-free survival rate was respectively: 95.9%, 93.1% and 82.5% (p = 0.02). In multivariate analysis, factors affecting overall survival rate were: age ≥65 ans (HR 3.62, p < 0.0001), FIGO stage (HR 3.33 p < 0.0001 for locally advanced stage versus early stage, HR 8.87 p = 0.03 for distant extension versus early stage), and group 3 (HR 2.83 p < 0.001 versus group 1). CONCLUSION Patients with endometrial cancer previously treated for breast cancer show a worse prognostic, particularly if they reveived tamoxifen.
Collapse
Affiliation(s)
- C Ngô
- Department of Surgical Oncology, Institut Curie, 26 rue d'Ulm, 75005 Paris, France.
| | - C Brugier
- Department of Surgical Oncology, Institut Curie, 26 rue d'Ulm, 75005 Paris, France
| | - C Plancher
- Department of Biostatistics, Institut Curie, 26 rue d'Ulm, 75005 Paris, France
| | | | - S Alran
- Department of Surgical Oncology, Institut Curie, 26 rue d'Ulm, 75005 Paris, France
| | - J G Féron
- Department of Surgical Oncology, Institut Curie, 26 rue d'Ulm, 75005 Paris, France
| | - C Malhaire
- Department of Medical Imaging, Institut Curie, 26 rue d'Ulm, 75005 Paris, France
| | - S Scholl
- Department of Medical Oncology, Institut Curie, 26 rue d'Ulm, 75005 Paris, France
| | - X Sastre
- Department of Pathology, Institut Curie, 26 rue d'Ulm, 75005 Paris, France
| | - R Rouzier
- Department of Surgical Oncology, Institut Curie, 26 rue d'Ulm, 75005 Paris, France
| | - V Fourchotte
- Department of Surgical Oncology, Institut Curie, 26 rue d'Ulm, 75005 Paris, France
| | | |
Collapse
|
31
|
Guillot E, Vaysse C, Goetgeluck J, Falcou MC, Couturaud B, Fitoussi A, Fourchotte V, Laki F, Malhaire C, Sigal-Zafrani B, Sastre-Garau X, Bollet MA, Mosseri V, Reyal F. Extensive pure ductal carcinoma in situ of the breast: identification of predictors of associated infiltrating carcinoma and lymph node metastasis before immediate reconstructive surgery. Breast 2013; 23:97-103. [PMID: 24388733 DOI: 10.1016/j.breast.2013.12.002] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/25/2013] [Revised: 08/28/2013] [Accepted: 12/01/2013] [Indexed: 11/25/2022] Open
Abstract
AIM To identify predictors for infiltrating carcinoma and lymph node involvement, before immediate breast reconstructive surgery, in patients with an initial diagnosis of extensive pure ductal carcinoma in situ of the breast (DCIS). PATIENTS AND METHODS Between January 2000 and December 2009, 241 patients with pure extensive DCIS in preoperative biopsy had underwent mastectomy. Axillary staging (sentinel node and/or axillary dissection) was performed in 92% (n = 221) of patients. Patients with micro-invasive lesions at initial diagnosis, recurrence or contralateral breast cancer were excluded. RESULTS Respectively 14% and 21% of patients had a final diagnosis of micro-invasive carcinoma (MIC) and invasive ductal carcinoma (IDC). Univariate analysis showed that the following variables at diagnosis were significantly correlated with the presence of either MIC or IDC in the mastectomy specimen: palpable tumor (p = 0.002), high grade DCIS (p = 0.002) and detection of an opacity by mammography (p = 0.019). Axillary lymph node (ALN) involvement was reported in 9% of patients. Univariate analysis suggested that a body mass index higher than 25 (p = 0.007), a palpable tumor (p = 0.012) and the detection of an opacity by mammography (p = 0.044) were associated with an increased rate of ALN involvement. CONCLUSION Skin-sparing mastectomy and immediate breast reconstruction (IBRS) has become increasingly popular, especially for patients with extended DCIS of the breast. This study confirmed that extended DCIS is associated with a substantial risk of finding MIC or IDC on the surgical specimen but also ALN involvement. Adjuvant systemic treatment and/or radiotherapy could be indicated for some of these patients after the surgery. Patients should be informed of the rate of 1) complications associated to IBRS that will potentially delay the introduction of systemic or local therapy 2) complications associated to radiotherapy after IBRS.
Collapse
Affiliation(s)
- E Guillot
- Department of Surgery, Institut Curie, 26 rue d'Ulm, 75005 Paris, France.
| | - C Vaysse
- Department of Surgery, Institut Curie, 26 rue d'Ulm, 75005 Paris, France
| | - J Goetgeluck
- Department of Surgery, Institut Curie, 26 rue d'Ulm, 75005 Paris, France
| | - M C Falcou
- Department of Biostatistics, Institut Curie, Paris, France
| | - B Couturaud
- Department of Surgery, Institut Curie, 26 rue d'Ulm, 75005 Paris, France
| | - A Fitoussi
- Department of Surgery, Institut Curie, 26 rue d'Ulm, 75005 Paris, France
| | - V Fourchotte
- Department of Surgery, Institut Curie, 26 rue d'Ulm, 75005 Paris, France
| | - F Laki
- Department of Surgery, Institut Curie, 26 rue d'Ulm, 75005 Paris, France
| | - C Malhaire
- Department of Radiology, Institut Curie, Paris, France
| | - B Sigal-Zafrani
- Department of Tumors' Biology, Institut Curie, Paris, France
| | - X Sastre-Garau
- Department of Tumors' Biology, Institut Curie, Paris, France
| | - M A Bollet
- Department of Radiotherapy, Institut Curie, Paris, France
| | - V Mosseri
- Department of Biostatistics, Institut Curie, Paris, France
| | - F Reyal
- Department of Surgery, Institut Curie, 26 rue d'Ulm, 75005 Paris, France
| |
Collapse
|
32
|
Thibault F, Dromain C, Breucq C, Balleyguier CS, Malhaire C, Steyaert L, Tardivon A, Baldan E, Drevon H. Digital breast tomosynthesis versus mammography and breast ultrasound: a multireader performance study. Eur Radiol 2013; 23:2441-9. [PMID: 23673573 DOI: 10.1007/s00330-013-2863-5] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/21/2013] [Revised: 03/13/2013] [Accepted: 03/15/2013] [Indexed: 12/17/2022]
Abstract
OBJECTIVES To compare the diagnostic performance of single-view breast tomosynthesis (BT) with that of dual-view mammography (MX); to assess the benefit of adding the craniocaudal (CC) mammographic view to BT, and of adding BT to MX plus breast ultrasound, considered to be the reference work-up. METHODS One hundred and fifty-five consenting patients with unresolved mammographic and/or ultrasound findings or breast symptoms underwent conventional work-up plus mediolateral oblique-view BT of the affected breast. The final study set in 130 patients resulted in 55 malignant and 76 benign and normal cases. Seven breast radiologists rated the cases through five sequential techniques using a BIRADS-based scale: MX, MX + ultrasound, MX + ultrasound + BT, BT, BT + MX(CC). Multireader, multicase receiver operating characteristic (ROC) analysis was performed and performance of the techniques was assessed from the areas under ROC curves. The performance of BT and of BT + MX(CC) was tested versus MX; the performance of MX + ultrasound + BT tested versus MX + ultrasound. RESULTS Tomosynthesis was found to be non-inferior to mammography. BT + MX(CC) did not appear to be superior to MX, and MX + ultrasound + BT not superior to MX + ultrasound. CONCLUSIONS Overall, none of the five techniques tested outperformed the others. Further clinical studies are needed to clarify the role of BT as a substitute for traditional work-up in the diagnostic environment. KEY POINTS • Digital breast tomosynthesis is a new adjunct to mammography and breast ultrasound. • We compared the diagnostic performance of these investigations in an experimental observer study. • Single-view breast tomosynthesis was confirmed as non-inferior to dual-view mammography. • None of the investigations (or combinations) tested outperformed the others. • Further prospective studies are needed to clarify precise role of tomosynthesis for diagnostic application.
Collapse
Affiliation(s)
- Fabienne Thibault
- Department of Radiology, Institut Curie, 26 rue d'Ulm, 75248, Paris Cedex 05, France.
| | | | | | | | | | | | | | | | | |
Collapse
|
33
|
Malhaire C. Comparison of two experimental methods for the mechanical characterization of thin or thick films from the study of micromachined circular diaphragms. Rev Sci Instrum 2012; 83:055008. [PMID: 22667649 DOI: 10.1063/1.4719964] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/01/2023]
Abstract
The purpose of this study was to compare two experimental methods and evaluate the effectiveness of a set of analytical models in order to measure the initial stress and the Young's modulus value of thin and thick film materials. Two types of experiments were performed on micromachined circular diaphragms: bulge testing and vibrometry. The range of validity and accuracy of the analytical models with respect to the vibration of the diaphragms was discussed from the finite element simulations. It was shown that the a/t ratio should be considered carefully to determine the value of the Young's modulus by vibrometry with an acceptable error. A relative error of approximately ±10% on E was obtained for a/t ≤ 750. For 750 ≤ a/t ≤ 1000, the value of the dimensionless parameter k must also be considered. It has been shown that the residual stress value can be obtained with an accuracy of 10% or less, given that k > 12. As an illustration, experimental methods and models were applied to the characterization of a thick electroplated gold film and a sputter-deposited Inconel thin film. Circular structures were defined by vertical sidewalls etched on the back of a Si wafer using the deep reactive ion etching technique. In addition to analytical models, parametric finite element simulations and a design optimization technique were used to determine the material's mechanical properties. The static deflections of the diaphragms were measured as a function of the applied pressure. The resonant frequencies and mode shapes of the vibrating structures were observed under vacuum by white-light interferometric microscopy. For gold, it was found that E = (53 ± 20) GPa and σ(0) = (180 ± 10) MPa. For Inconel, it was found that E = (157 ± 14) GPa and σ(0) = (172 ± 5) MPa.
Collapse
Affiliation(s)
- C Malhaire
- Université de Lyon, Institut des Nanotechnologies de Lyon INL-UMR5270, CNRS, INSA de Lyon, 7 av. Jean Capelle, bât. Blaise Pascal, Villeurbanne, F-69621, France
| |
Collapse
|
34
|
Guillot E, Goetgheluck J, Couturaud B, Fitoussi A, Salmon RJ, Malhaire C, Falcou MC, Mosseri V, Sastre X, Bollet MA, Reyal F. Abstract P5-14-18: Extended Pure Ductal Carcinoma In Situ of the Breast on Preoperative Biopsies. Prognostic Factors for Infiltrating Carcinoma and Lymph Node Involvement. Cancer Res 2010. [DOI: 10.1158/0008-5472.sabcs10-p5-14-18] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Introduction: The aim of our study was to identify predictive factors of infiltrating carcinoma and lymph node involvement in patients with an initial diagnosis of extended pure ductal carcinoma in situ (DCIS) of the breast.
Material and Methods: 241 patients diagnosed with extended pure ductal carcinoma in situ (DCIS) underwent treatment at the Institut Curie (2000-2009) consisting of mastectomy with or without immediate breast reconstruction (IMR). Axillary staging (sentinel node and/or standard procedure) was performed in 92% of patients. Patients with micro-invasive lesions at diagnosis, recurrence or contralateral breast cancer were excluded. Differences between groups were analysed by Chi-square or Fisher Exact tests for categorical variables and Student's t-test for continuous variables. Survival analyses were performed using KaplanMeier, with comparisons using the logrank test and hazard ratios estimated using the Cox proportional hazard model. P-values were considered significant when below 0.05.
Results: Respectively 15% and 20%of patients had a final diagnosis of micro-invasive (MIC) and invasive ductal carcinoma (IDC). The median sizes of the DCIS and IDC were respectively 40mm [0-95] and 6mm [2-50] according to final histological assessment. Univariate analysis showed that the following variables at diagnosis were significantly correlated to the presence of either MIC or IDC in the mastectomy specimen; palpable tumor (p=0.02), high grade DCIS (p=0.02), detection of an opacity on mammography (p=0.01). Axillary lymph node involvement was reported in 9% of patients. In univariate analysis a BMI>25 (p=0.007), a palpable tumor (p=0.01), the detection of an opacity (p=0.04) were associated with an increase rate of lymph node involvement. A IMR was performed in 69% of patients. These patients were younger (P<0.00001), thinner (p=0.005), with fewer palpable tumors (p=0.01), and DCIS of lower grades (p=0.03) than patients denied of breast MRI. With a median follow-up of 30 months, 7 patients (3%) experience locoregional recurrence. In univariate analysis a BMI>25 (p=0.06), a palpable tumor (p=0.0004), an opacity (p=0.01) and extended microcalcifications (p=0.02) were associated with a higher rate of loco-regional recurrence. Immediate breast reconstruction was not a significant risk factor for loco-regional recurrence (p=0.31). Conclusion: Extended pure ductal carcinoma of the breast on preoperative biopsies is associated with a substantial risk of finding not only micro-invasive or invasive carcinoma on the mastectomy specimen but also axillary lymph node involvement. Some risk factors have been identified and should be used to exclude patients from immediate reconstruction surgery due to an increased risk of getting adjuvant systemic treatment and radiotherapy. Immediate breast reconstructive surgery was not associated with an increased risk of loco regional recurrence in our series.
Citation Information: Cancer Res 2010;70(24 Suppl):Abstract nr P5-14-18.
Collapse
Affiliation(s)
- E Guillot
- Institut Curie, Paris, France, Metropolitan; Institut Curie
| | - J Goetgheluck
- Institut Curie, Paris, France, Metropolitan; Institut Curie
| | - B Couturaud
- Institut Curie, Paris, France, Metropolitan; Institut Curie
| | - A Fitoussi
- Institut Curie, Paris, France, Metropolitan; Institut Curie
| | - RJ Salmon
- Institut Curie, Paris, France, Metropolitan; Institut Curie
| | - C Malhaire
- Institut Curie, Paris, France, Metropolitan; Institut Curie
| | - M-C Falcou
- Institut Curie, Paris, France, Metropolitan; Institut Curie
| | - V Mosseri
- Institut Curie, Paris, France, Metropolitan; Institut Curie
| | - X Sastre
- Institut Curie, Paris, France, Metropolitan; Institut Curie
| | - MA Bollet
- Institut Curie, Paris, France, Metropolitan; Institut Curie
| | - F. Reyal
- Institut Curie, Paris, France, Metropolitan; Institut Curie
| |
Collapse
|
35
|
Malhaire C, Boyer B, Danguy des Déserts M, Sissakian JF, Tardivon A. [Pseudoaneurysm of the breast following percutaneous biopsy]. J Radiol 2010; 91:809-811. [PMID: 20814366 DOI: 10.1016/s0221-0363(10)70120-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/29/2023]
|
36
|
Tardivon A, Malhaire C, Athanasiou A, Thibault F, El Khoury C. E11. Advances in breast cancer imaging. EJC Suppl 2010. [DOI: 10.1016/s1359-6349(10)70015-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022] Open
|
37
|
Malhaire C, El Khoury C, Thibault F, Athanasiou A, Petrow P, Ollivier L, Tardivon A. Vacuum-assisted biopsies under MR guidance: results of 72 procedures. Eur Radiol 2010; 20:1554-62. [PMID: 20119729 DOI: 10.1007/s00330-009-1707-9] [Citation(s) in RCA: 61] [Impact Index Per Article: 4.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/23/2009] [Revised: 10/31/2009] [Accepted: 11/16/2009] [Indexed: 11/25/2022]
Abstract
OBJECTIVE To investigate the clinical accuracy of magnetic resonance imaging-guided breast vacuum-assisted biopsy (MR-VAB). METHODS Of 97 scheduled MR-VAB for single MRI lesions (negative second-look sonography) categorised as BI-RADS 4 or 5, 4 were cancelled (undetected lesion = 2, technical problems = 2). Twenty-one patients lost to follow-up were excluded. RESULTS Twenty-three patients (median age 51 years) were at high risk (BRCA1 = 11, BRCA2 = 7, familial risk = 5), 23 had a suspected local recurrence of breast cancer. Seventy-two imaged lesions (focus = 1, mass enhancement = 32, non-mass-like enhancement = 39) were targeted with a 10-gauge VAB probe using MRI guidance, with a median of 18 specimens per lesion (median procedural time 72 min, range 50-131 min) followed by clip placement. In the case of benignity, MRI follow-up was performed (19 patients, median 389 days, range 33-1,592) or mammography (3 patients, median 420 days, range 372-1,354). According to histopathology results, 29 lesions were benign, 10 were high-risk (papillary = 2, radial scar = 1, atypical epithelial hyperplasia = 7) and 33 malignant (ductal carcinoma in situ = 8, invasive cancers = 25). Three false negative results and 3 complications occurred (1 malaise, 1 skin defect, 1 infection). CONCLUSION MRI-guided VAB represents an accurate tool for the histological diagnosis of lesions visible only at MRI.
Collapse
Affiliation(s)
- C Malhaire
- Radiology Department, Institut Curie, Paris, France.
| | | | | | | | | | | | | |
Collapse
|
38
|
Martegoutte J, Seguineau C, Fourcade T, Malhaire C, Martins P, Desmarres J, Lafontan X. Influence of microstructure and internal stress on the mechanical behavior of electroplated gold freestanding thin films. EPJ Web of Conferences 2010. [DOI: 10.1051/epjconf/20100626009] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
|
39
|
Touraine S, Malhaire C, Thibault F, Athanasiou A, Ollivier L, Tardivon A. Thoracic CT scan: its contribution to diagnosis and interventional procedures in breast imaging. Cancer Imaging 2010. [DOI: 10.1102/1470-7330.2010.9079] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
|
40
|
Servois V, Mariani P, Malhaire C, Petras S, Piperno-Neumann S, Plancher C, Levy-Gabriel C, Lumbroso-le Rouic L, Desjardins L, Salmon RJ. Preoperative staging of liver metastases from uveal melanoma by magnetic resonance imaging (MRI) and fluorodeoxyglucose-positron emission tomography (FDG-PET). Eur J Surg Oncol 2009; 36:189-94. [PMID: 19775851 DOI: 10.1016/j.ejso.2009.08.010] [Citation(s) in RCA: 42] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/17/2009] [Revised: 08/18/2009] [Accepted: 08/23/2009] [Indexed: 10/20/2022] Open
Abstract
BACKGROUND Microscopically complete (R0) resection of metastases from uveal melanoma prolongs median overall survival compared to incomplete surgery. The aim of this study was to compare the sensitivity of dynamic-enhanced magnetic resonance imaging (MRI) with fluorodeoxyglucose-positron emission tomography (FDG-PET) in the preoperative diagnosis of liver metastases from uveal melanoma. PATIENTS AND METHODS Fifteen consecutive patients (mean age: 56 years) underwent FDG-PET and liver MRI. Extrahepatic metastatic disease was excluded by whole body computed tomography and bone scintigraphy. MRI and FDG-PET were performed with a mean of 19 days (range: 1-30) before surgery. Imaging findings were compared with surgical (including intraoperative ultrasonography) and histological findings on a lesion by lesion analysis. RESULTS R0 resection was performed in 12 patients. A total of 28 lesions were resected with 27 histologically proven metastases. Nine lesions were smaller than 5mm, 7 measured 5-10mm and 11 were larger than 10mm. Sensitivity and positive predictive value were 67% and 95% for MRI compared to 41% and 100% for FDG-PET. The difference between the two modalities was statistically significant (p=0.01; McNemar test). In remaining 3 patients, diffuse miliary disease (>10 capsular lesions) was discovered intraoperatively, and was suspected on preoperative MRI in 2 cases. Only one extrahepatic lesion identified by FDG-PET was falsely positive. CONCLUSIONS In this preliminary study, MRI was superior to FDG-PET for staging of liver metastases from uveal melanoma. Although miliary disease was suggested by MRI in some cases, preoperative confirmation remains imperfect.
Collapse
Affiliation(s)
- V Servois
- Department of Radiology and Nuclear Medicine, Institut Curie, 26 rue d'Ulm, 75248 Paris Cedex 05, France
| | | | | | | | | | | | | | | | | | | |
Collapse
|
41
|
|
42
|
Daguet E, Malhaire C, Hardit C, Athanasiou A, El Khoury C, Thibault F, Ollivier L, Tardivon A. MR Breast screening in patients with genetic mutation. Clin Imaging 2009. [DOI: 10.1016/j.clinimag.2008.10.012] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
43
|
Renaud L, Malhaire C, Kleimann P, Barbier D, Morin P. Theoretical and experimental studies of microflows in silicon microchannels. Materials Science and Engineering: C 2008. [DOI: 10.1016/j.msec.2007.10.070] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
44
|
Thibault F, Bollet MA, Tardivon A, Malhaire C, Zemmour-Elfersi G. Evaluating tumour response to primary radiochemotherapy in breast cancer patients: what role for breast magnetic resonance imaging? Breast Cancer Res 2008. [PMCID: PMC3332585 DOI: 10.1186/bcr2013] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
45
|
Daguet E, Malhaire C, Hardit C, Athanasiou A, El Khoury C, Thibault F, Ollivier L, Tardivon A, Tardivon A. Dépistage du cancer du sein par IRM chez les femmes porteuses d’une mutation génétique. ACTA ACUST UNITED AC 2008; 89:783-90. [DOI: 10.1016/s0221-0363(08)73784-3] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
46
|
Sorgho-Lougue LC, Luciani A, Kobeiter H, Zelek L, Malhaire C, Deux JF, Brun B, Piedbois P, Rahmouni A. Adenocarcinomas of unknown primary (ACUP) of the mediastinum mimicking lymphoma: CT findings at diagnosis and follow-up. Eur J Radiol 2006; 59:42-8. [PMID: 16504446 DOI: 10.1016/j.ejrad.2006.01.010] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/23/2005] [Accepted: 01/24/2006] [Indexed: 10/25/2022]
Abstract
OBJECTIVE To describe the computed tomography (CT) features at diagnosis and after treatment of adenocarcinoma of unknown primary (ACUP) mimicking lymphoma of the mediastinum. METHODS Fifteen patients with pathologically proven ACUP and with primarily mediastinal involvement were initially referred to the Hematologic Department of our institution with a suspected diagnosis of lymphoma, and accounted for our study population. Presenting symptoms and baseline biological values were analyzed. All thoraco-abdominal CT studies were reviewed for the location and size of the mediastinal involvement and associated findings. Follow-up chest CT was performed in 14 patients after radiotherapy, chemotherapy or surgical treatment. RESULTS The most frequent CT feature was a large anterior and middle mediastinal mass (67%), with no calcification. Associated findings included the presence of lung nodules (40%), compression of large mediastinal vessels (33%) and pleural effusion (27%). Follow-up CT, performed in 14 cases, suggested partial or complete responses in 7 patients (50%) 4 weeks after the treatment onset. CONCLUSIONS Mediastinal ACUP is a differential diagnosis of large mediastinal masses and is frequently associated with lung nodules and mediastinal vascular compression.
Collapse
Affiliation(s)
- Leonie Claudine Sorgho-Lougue
- Department of Radiology, Centre Hospitalo-Universitaire Henri Mondor, Imagerie Medicale, 51 Avenue du Marechal de Lattre de Tassigny, 94010 Créteil, France
| | | | | | | | | | | | | | | | | |
Collapse
|
47
|
Abstract
The identification of dilatations of the intrahepatic bile ducts in the absence of bile duct obstruction is rare. Imaging techniques, especially MR cholangio-pancreaticography, generally permit the distinction between fibrocystic liver diseases and polycystic liver diseases. The presence of dilated sacciform or tubular bile ducts on cholangio-pancreaticography associated with a centrally located fibrovascular bundle (central dot sign) suggests Caroli's syndrome. The presence of associated signs of liver dysmorphia including right lobe atrophy and hypertrophy of segment IV suggests associated congenital hepatic fibrosis. The findings on cholangio-pancreaticography, computerized tomography or Doppler ultrasonography correlate well with the pathogenesis of fibrocystic liver diseases, linked to an embryologic malformation of the ductal plate.
Collapse
Affiliation(s)
- Alain Luciani
- Service d'Imagerie Médicale, Centre hospitalo-universitaire Henri Mondor, Créteil.
| | | | | | | | | | | | | |
Collapse
|
48
|
Malhaire C, Garot J, Rahmouni A. MR demonstration of septal involvement in arrhythmogenic right ventricular dysplasia. Eur Radiol 2004; 15:881-3. [PMID: 15351904 DOI: 10.1007/s00330-004-2470-6] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/08/2004] [Revised: 06/29/2004] [Accepted: 08/03/2004] [Indexed: 11/30/2022]
Abstract
Arrhythmogenic right ventricular dysplasia (ARVD) is a heart muscle disease of unknown origin. Although MR imaging is regarded as the best technique for the demonstration of functional and structural abnormalities in ARVD, fat deposits in the interventricular septum have never been documented on MR imaging. We report the case of interventricular septal fatty deposition demonstrated by fat-suppressed MR imaging in a 48-year-old man.
Collapse
Affiliation(s)
- Caroline Malhaire
- Service de Radiologie et d'Imagerie Médicale, Centre Hospitalo-Universitaire Henri Mondor, Créteil, France.
| | | | | |
Collapse
|